Introduction

More than 30 antiretroviral (ARV) drugs in seven mechanistic classes are Food and Drug Administration (FDA)-approved for treatment of HIV infection. These seven classes include the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), a fusion inhibitor, a CCR5 antagonist, and a CD4 post-attachment inhibitor. In addition, two drugs, ritonavir (RTV or r) and cobicistat (COBI or c) are used as pharmacokinetic (PK) enhancers (or boosters) to improve the PK profiles of some ARV drugs (e.g., PIs and the INSTI elvitegravir [EVG]).

The initial ARV regimen for a treatment-naive patient generally consists of two NRTIs, usually abacavir/lamivudine (ABC/3TC) or either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate (TDF)/FTC, plus a drug from one of three drug classes: an INSTI, an NNRTI, or a boosted PI. As shown in clinical trials and by retrospective evaluation of cohorts of patients in clinical care, this strategy for initial treatment has resulted in suppression of HIV replication and CD4 T lymphocyte (CD4) cell count increases in most persons with HIV.1-3 Emerging data support the use of two-drug regimens, such as...
dolutegravir (DTG) plus 3TC, when ABC, TDF, and TAF cannot be used or are not optimal (see the section below titled Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal).

Supporting Evidence and Rationale Used for the Panel’s Recommendations

The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel)’s recommendations are primarily based on clinical trial data published in peer-reviewed journals and data prepared by manufacturers for FDA review. In select cases, the Panel considers data from abstracts presented at major scientific meetings. The Panel considers published information from a randomized, prospective clinical trial with an adequate sample size that demonstrates that an ARV regimen produces high rates of viral suppression, increases CD4 count, and has a favorable safety profile to be the strongest evidence on which to base recommendations. Comparative clinical trials of initial treatments generally show no significant differences in HIV-related clinical endpoints or survival. Thus, assessment of regimen efficacy and safety are primarily based on surrogate marker endpoints (especially rates of HIV RNA suppression) and the incidence and severity of adverse events.

In some instances, the Panel recommends regimens that include medications approved by the FDA based on bioequivalence or relative bioavailability studies demonstrating that the exposure of the drug(s) in the new formulation or combination is comparable to the exposure of a reference drug(s) that has demonstrated safety and efficacy in randomized clinical trials. When developing recommendations, the Panel may also consider data from randomized switch studies, in which a new medication replaces an existing medication from the same class in patients who have achieved virologic suppression on an initial regimen. Switch trials do not evaluate the ability of a drug or regimen to induce viral suppression; they only examine the drug or regimen’s ability to maintain suppression. Therefore, results from switch trials may not be directly applicable to the selection of an initial regimen and should be considered in conjunction with other data, including data from trials conducted in treatment-naive patients and bioequivalence/bioavailability studies. In this section of the guidelines, the definition of an evidence rating of II is expanded to include supporting data from bioavailability/bioequivalence studies or randomized switch studies.

When developing recommendations, the Panel also considers tolerability and toxicity profiles, pill burden and dosing frequency, drug interaction potential, cost and access, post-marketing safety data, observational cohort data published in peer-reviewed publications, and the experience of clinicians and community members who are actively engaged in patient care.

The Panel reviewed the available data to arrive at two regimen classifications for ARV-naive patients: (1) Recommended Initial Regimens for Most People with HIV and (2) Recommended Initial Regimens in Certain Clinical Situations (Table 6a). Recommended Initial Regimens for Most People with HIV are those regimens with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use. The Panel also recognizes that, in certain clinical situations, other regimens may be preferred; these options are included in Table 6a in the category of Recommended Initial Regimens in Certain Clinical Situations. Examples of clinical scenarios in which certain drugs in these regimens may be particularly advantageous are outlined in Table 7.

There are many other ARV regimens that are effective for initial therapy but have disadvantages when compared with the regimens listed in Table 6a. These disadvantages include greater toxicity, higher pill burden, less supporting data from large comparative clinical trials, or limitations for use in certain patient populations. These other regimens are no longer included in Table 6a. A person with HIV who is virologically suppressed and who is not experiencing any adverse effects on a regimen that is not listed in Table 6a need not necessarily change to a regimen that is in that table. Clinicians should refer to Optimizing Antiretroviral Therapy in the Setting of Viral Suppression for further guidance if switching to a new regimen is desired.
Regimens and medications listed in Table 10 are not recommended as initial ARV. In most instances, a clinician is urged to consider switching a patient who is on one of the regimens listed in Table 10 to a recommended regimen.

In addition to these tables, several tables presented below and at the end of these guidelines provide clinicians with guidance on selecting and prescribing an optimal regimen for an individual patient. Table 9 lists the potential advantages and disadvantages of the different ARV drug components. Appendix B, Tables 1–7 list characteristics of individual ARV agents (e.g., formulations, dosing recommendations, PKs, common adverse effects). Appendix B, Table 8 provides ARV dosing recommendations for patients who have renal or hepatic insufficiency.

Changes Since the Last Revision of the Guidelines

Since the last revision of the Adult and Adolescent Guidelines, there have been several important changes in the Panel’s recommendations for initial therapy in people with HIV. Among these changes, the following deserve particular emphasis:

INSTITI-Based Regimens as Initial Antiretroviral Therapy:

• Bictegravir (BIC)/TAF/FTC has been added to the category of Recommended Initial Regimens for Most People with HIV (AI). This regimen was added based on data from randomized Phase 3 clinical trials that demonstrated that its efficacy, safety, and tolerability are similar to other regimens that are recommended for most people with HIV—namely, dolutegravir (DTG)/ABC/3TC and DTG plus TAF/FTC.4,5

• EVG/c/TDF/FTC and EVG/c/TAF/FTC (BI) have been moved from the category of Recommended Initial Regimens for Most People with HIV to the category of Recommended Initial Regimens in Certain Clinical Situations. This change was made because these combinations include COBI, a pharmacoenhancer that inhibits cytochrome P (CYP) 3A4 and increases the likelihood of drug-drug interactions. EVG also has a lower barrier to resistance than DTG and BIC.

• Clinicians should review Table 6b before prescribing an INSTI to a person of childbearing potential, as preliminary data suggest that there is an increased risk of neural tube defects (NTDs) in infants born to people who were receiving DTG at the time of conception.6,7 Until more information is available:
  • A negative pregnancy test result should be documented prior to initiating DTG in antiretroviral therapy (ART)-naive individuals of childbearing potential.
  • DTG is not recommended for those who are pregnant and within 12 weeks post-conception.
  • DTG is also not recommended for those of childbearing potential who are planning to become pregnant or who are sexually active and not using effective contraception.
  • For those who are using effective contraception, use of a DTG-based regimen can be considered after discussing the risks and benefits of this drug with the patient.
  • It is not yet known whether other INSTIs pose a similar risk of NTDs (i.e., a class effect). The chemical structure of BIC is similar to that of DTG. As there are no safety data for BIC use around the time of conception, similar considerations should be discussed with those of childbearing potential before using this drug.

NNRTI-Based Regimens as Initial Antiretroviral Therapy:

• The regimen of doravirine (DOR) plus TDF/3TC or TAF/FTC has been added to the category of Recommended Initial Regimens in Certain Clinical Situations. DOR is a new NNRTI that was recently approved for use in ART-naive individuals when administered with two NRTIs. DOR/TDF/3TC is coformulated as a single-tablet regimen (STR). Clinical trial data have shown that this regimen is noninferior to efavirenz (EFV)- and darunavir/ritonavir (DRV/r)-based regimens.8,9 DOR compares...
favorsably to EFV and DRV/r in terms of side effects. DOR-based therapy has not been directly compared to INSTI-containing combinations for initial therapy. In patients starting their first ART regimen, treatment-emergent resistance to DOR has been observed.

- EFV 400 mg/TDF/3TC and EFV 600 mg/TDF/FTC are now available as generic STRs. In a randomized trial (ENCORE-1), EFV 400 mg/TDF/3TC and EFV 600 mg/TDF/3TC had similar virologic efficacy, though EFV 400 mg/TDF/3TC had fewer side effects. There are insufficient data regarding the use of EFV 400 mg/TDF/3TC in pregnancy or in people receiving rifampin to recommend its use in these situations. See the NNRTI section below for considerations regarding the use of these two single-pill regimens.

Protease Inhibitor-Based Regimens as Initial Antiretroviral Therapy:

- Boosted atazanavir (ATV/c or ATV/r) plus ABC/3TC is no longer included in the list of Recommended Initial Regimens in Certain Clinical Situations because it has disadvantages when compared with other regimens in this category. In a randomized trial, ATV/r plus ABC/3TC was less potent than ATV/r plus TDF/FTC in people with HIV RNA >100,000 copies/mL. In a separate randomized trial, ATV/r was less well tolerated than DRV/r.11

Other Regimens When Abacavir, Tenofovir Alafenamide, or Tenofovir Disoproxil Fumarate Cannot be Used or Are Not Optimal:

- DTG plus 3TC is now recommended by the Panel when ABC, TAF, or TDF cannot be used or are not optimal. This is based on the results of two large Phase 3 randomized clinical trials: DTG plus 3TC was noninferior to DTG plus TDF/FTC in terms of virologic efficacy, and no drug resistance was seen in either treatment group. Longer-term data are needed before this new two-drug regimen is recommended for most people with HIV.

- Other regimens that can be considered are DRV/r plus raltegravir (RAL), as long as a patient’s plasma HIV RNA is <100,000 copies/mL and CD4 cell count is >200/mm³, or DRV/r plus 3TC, although the data for this regimen are not as extensive as for other combinations.

- Lopinavir/ritonavir (LPV/r) plus 3TC is no longer recommended because of pill burden and poor tolerability.

Generic Antiretroviral Drugs:

- A growing number of generic ARV medications have been approved by the FDA since the last revision of these guidelines. In some situations, cost and access are among the factors to consider when choosing an ARV regimen (see Cost Considerations and Antiretroviral Therapy).
### Table 6a. Recommended Antiretroviral Regimens for Initial Therapy

Selection of a regimen should be individualized based on virologic efficacy, potential adverse effects, childbearing potential and use of effective contraception, pill burden, dosing frequency, drug-drug interaction potential, comorbid conditions, cost, access, and resistance test results. Drug classes and regimens within each class are arranged first by evidence rating, and, when ratings are equal, in alphabetical order. Table 7 provides ARV recommendations based on specific clinical scenarios.

<table>
<thead>
<tr>
<th>Recommended Initial Regimens for Most People with HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommended regimens are those with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use.</td>
</tr>
<tr>
<td>INSTI plus 2 NRTIs:</td>
</tr>
<tr>
<td><strong>Note:</strong> For individuals of childbearing potential, see Table 6b before prescribing one of these regimens.</td>
</tr>
<tr>
<td>• <strong>BIC/TAF/FTC</strong> (AI)</td>
</tr>
<tr>
<td>• <strong>DTG/ABC/3TC</strong> (AI)—if HLA-B*5701 negative</td>
</tr>
<tr>
<td>• DTG plus tenofovir/FTC (AI for both TAF/FTC and TDF/FTC)</td>
</tr>
<tr>
<td>• RAL plus tenofovir/FTC (BI for TDF/FTC, BII for TAF/FTC)</td>
</tr>
</tbody>
</table>

### Recommended Initial Regimens in Certain Clinical Situations

These regimens are effective and tolerable but have some disadvantages when compared with the regimens listed above or have less supporting data from randomized clinical trials. However, in certain clinical situations, one of these regimens may be preferred (see Table 7 for examples).

| INSTI plus 2 NRTIs: |
| **Note:** For individuals of childbearing potential, see Table 6b before prescribing one of these regimens. |
| • **E VG/c/tenofovir/FTC** (BI for both TAF/FTC and TDF/FTC) |
| • RAL plus ABC/3TC (CII)—if HLA-B*5701 negative and HIV RNA <100,000 copies/mL |

| Boosted PI plus 2 NRTIs: (In general, boosted DRV is preferred over boosted ATV) |
| • (DRV/c or DRV/r) plus tenofovir/FTC (AI) |
| • (ATV/c or ATV/r) plus tenofovir/FTC (BI) |
| • (DRV/c or DRV/r) plus ABC/3TC— if HLA-B*5701 negative (BII) |

| NNRTI plus 2 NRTIs: |
| • **DOR/TDF/3TC** (BI) or **DOR plus TAF/FTC** (BIII) |
| • EFV plus TDF/FTC (BI for EFV 600 mg/TDF/FTC or EFV 600 mg/TDF/3TC, BII for EFV 600 mg plus TAF/FTC) |
| • RPV/tenofovir/FTC (BI)—if HIV RNA <100,000 copies/mL and CD4 cell count >200 cells/mm³ |

Regimens to Consider when ABC, TAF, and TDF Cannot be Used or Are Not Optimal:

| • DTG plus 3TC (BI) |
| • DRV/r plus RAL BID (CI)—if HIV RNA <100,000 copies/mL and CD4 cell count >200 cells/mm³ |
| • DRV/r once daily plus 3TC (CI) |

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies; III = Expert opinion

**Note:** The following are available as coformulated drugs: ABC/3TC, ATV/c, **BIC/TAF/FTC**, DOR/TDF/3TC, DRV/c, **DRV/c/TAF/FTC**, DTG/ABC/3TC, **EFV 600 mg/TDF/3TC**, EFV/TDF/FTC, **EVG/c/TAF/FTC**, **EVG/c/TDF/FTC**, RPV/TAF/FTC, RPV/TDF/FTC, TAF/FTC, **TDF/3TC**, and TDF/FTC.

a 3TC may be substituted for FTC, or vice versa. ABC/3TC, TDF/3TC, TDF/FTC, and TAF/FTC are available as coformulated, two-NRTI tablets, and they are also available as part of various STRs. Cost, access, and availability of STR formulations are among the factors to consider when choosing between 3TC and FTC.

b TAF and TDF are two forms of tenofovir approved by the FDA. TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs.

c RAL can be given as RAL 400 mg BID or RAL 1200 mg (two, 600-mg tablets) once daily.
Table 6b. Considerations Before Initiating Dolutegravir and Other Integrase Strand Transfer Inhibitors as Initial Therapy

Pregnancy testing should be performed in those of childbearing potential prior to initiation of ART (AIII). Preliminary data suggest that there is an increased risk of NTDs in infants born to women who were receiving DTG at the time of conception.6,7 Before Initiating DTG:

• Providers and people of childbearing potential should discuss the benefits and risks of using DTG, including the possible risk of NTDs; appropriate counseling should be provided so that the individual can make an informed decision about the use of this drug (AIII).

• DTG should not be prescribed for individuals:
  • Who are pregnant and within 12 weeks post-conception (AII); or
  • Who are of childbearing potential and planning to become pregnant (AII); or
  • Who are of childbearing potential, sexually active, and not using effective contraception (AIII).

• For those who are using effective contraception, a DTG-based regimen can be considered after weighing the risks and benefits of DTG use with the individual (BIII).

• It is not yet known whether other INSTIs pose a similar risk of NTDs (i.e., a class effect).

• The chemical structure of BIC is similar to DTG. There are no safety data on the use of BIC around the time of conception. For those who are of childbearing potential, but who are not pregnant, an approach similar to that outlined for DTG should be discussed before considering the use of BIC-containing ART (AIII).

• In a person who is pregnant, BIC is not recommended because of insufficient safety data (AIII).

• In a person who is pregnant, EVG/c is also not recommended because low EVG concentrations have been reported when this drug is given during the second and third trimesters (AII).13

• Among those who received RAL during pregnancy, the rate of fetal malformations is within the expected range for pregnancy outcomes in the United States; however, data on RAL use during the first trimester is limited to fewer than 300 deliveries. As it is currently not known whether the association between DTG and NTDs represents a class effect, this potential risk should be discussed with people of childbearing potential who prefer an INSTI-containing regimen.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies; III = Expert opinion

Key to Acronyms: ART = antiretroviral therapy; BIC = bictegravir; DTG = dolutegravir; EVG/c = elvitegravir/cobicistat; INSTI = integrase strand transfer inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; RVP = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
The Panel’s Recommended Initial Regimens for Most People with HIV as listed in Table 6a include one of three INSTIs (BIC, DTG, or RAL) plus two NRTIs. For most patients, these INSTI-containing regimens will be highly effective and have relatively infrequent adverse effects and few drug interactions. In several head-to-head comparisons between boosted PI-containing regimens and INSTI-containing regimens, the INSTI was better tolerated and caused fewer treatment discontinuations.11,14,15

Among the INSTI-based regimens, RAL-containing regimens have the longest clinical experience, and they have been shown to have durable virologic efficacy. However, these regimens have a higher pill burden than BIC- and DTG-containing regimens. RAL also has a lower barrier to resistance than BIC and DTG. In clinical trials of ART-naive patients who were receiving BIC- or DTG-based therapy, resistance has not been seen in patients experiencing virologic failure, and transmitted resistance is rare. Because of its high barrier to resistance, DTG may be considered for patients who must start ART before resistance test results are available (e.g., during acute HIV infection, and in the setting of certain opportunistic infections). BIC may also be effective in this setting, but there is less clinical experience with it than with DTG. BIC-based regimens have been shown to be noninferior to DTG-based regimens in clinical trials.43 DG is not recommended as initial therapy in those who are pregnant and within 12 weeks post-conception, or in those of childbearing potential who are planning to become pregnant or who are sexually active and not using effective contraception. The safety of BIC use in individuals of childbearing potential who desire pregnancy is unknown.

In the category of Recommended Initial Regimens in Certain Clinical Situations, EVG-based regimens have the advantage of being available as STRs. However, these regimens have the potential disadvantages of a lower barrier to resistance than DTG or BIC and, importantly, a greater potential for drug interactions because EVG is combined with COBI, a strong CYP3A4 inhibitor. PK-enhanced, PI-based regimens are also effective in ART-naive patients, but, like EVG/c-based regimens, they also carry the same disadvantage of increased drug interaction potential. For those individuals in whom ART needs to begin urgently before resistance test results are available, boosted DRV may be an appropriate choice, as there is a low rate of transmitted PI resistance, it has a high barrier to resistance, and there is a low rate of treatment-emergent resistance. DRV/c/ TAF/FTC is now available as an STR. Boosted atazanavir has relatively few metabolic adverse effects in comparison to other boosted-PI regimens; however, in a randomized clinical trial, ATV/r had a higher rate of adverse effect-associated drug discontinuation than DRV/r or RAL.11 In a study of this trial, and in a separate cohort study, ATV/r use was associated with slower progression of atherosclerosis, as measured by carotid artery intima medial thickness.16,17 Large observational cohorts found an association between some PIs (DRV/r, fosamprenavir [FPV], indinavir [IDV], and lopinavir/ritonavir [LPV/r]) and an increased risk of cardiovascular events, while this association was not seen with ATV.18-23 Further study is needed.

NNRTI-based regimens (which include DOR, EFV, or rilpivirine [RPV]) may be optimal choices for some patients, although these drugs, especially EFV and RPV, have low barriers to resistance. The emergence of resistance at the time of virologic failure has been reported with DOR. EFV has a long track record of widespread use and is considered safe in persons of childbearing potential, and its minimal PK interaction with rifamycins makes it an attractive option for patients who require concomitant treatment for tuberculosis (TB). Most EFV-based regimens have excellent virologic efficacy, including in patients with high HIV RNA (except when EFV is used with ABC/3TC); however, the relatively high rate of central nervous system (CNS)-related side effects reduces the tolerability of EFV-based regimens. RPV has fewer adverse effects than EFV, is available as one of the smallest tablet sizes among STRs, and has a favorable lipid profile. However, RPV has lower virologic efficacy in patients with high baseline HIV RNA levels (>100,000 copies/mL) and low CD4 counts (<200 cells/mm³). DOR is now approved for use in ART-naive individuals with HIV. It is available both as a single-drug pill to be used with two NRTIs and as part of an STR that also includes TDF/3TC. Both formulations are taken once daily without regard to food. In randomized trials, DOR was noninferior to both EFV and to DRV/r when either of these drugs were taken in combination with two NRTIs. DOR has CNS tolerability advantages over EFV and favorable lipid effects when compared...
with both DRV/r and EFV. It also has fewer potential drug interactions than EFV or RPV, and, unlike RPV, virologic effects are not compromised in those with high HIV RNA levels and low CD4 cell counts.

In those patients who cannot safely be prescribed a combination regimen that contains two NRTIs, there are now several two-drug treatment options. DTG plus 3TC is an option when ABC, TAF, and TDF cannot be used or are not optimal. Two randomized trials that collectively enrolled >1,400 participants with baseline HIV RNA levels <500,000 copies/mL compared DTG plus 3TC to a three-drug regimen of DTG plus TDF/FTC. At week 48, DTG plus 3TC was noninferior to DTG plus TDF/FTC in terms of virologic efficacy. No treatment-emergent resistance was seen in either group. Another option that can be considered is the combination of DRV/r (once daily) plus RAL (twice daily), but this combination can only be used in those with baseline CD4 cell counts >200 cells/mm³ and HIV RNA levels <100,000 copies/mL. A small, randomized trial indicated that once-daily DRV/r plus 3TC had similar efficacy to DRV/r plus TDF/3TC, although this study has yet to be published.

Factors to Consider When Selecting an Initial Regimen

When selecting a regimen for an individual person with HIV, a number of patient- and regimen-specific characteristics should be considered. The goal is to provide a potent, safe, tolerable, and easy-to-adhere-to regimen for the patient in order to achieve sustained virologic control. Some of the factors to consider during regimen selection can be grouped into the categories listed below. Table 7 includes recommendations for regimens to use in specific clinical scenarios.

Initial Characteristics to Consider in All Persons with HIV:

• Pretreatment HIV RNA level (viral load)
• Pretreatment CD4 count
• HIV genotypic drug resistance test results. Based on current rates of transmitted drug resistance to different ARV medications, standard genotypic drug-resistance testing in ARV-naive persons should focus on testing for mutations in the reverse transcriptase (RT) and protease (PR) genes. If transmitted INSTI resistance is a concern, providers should consider also testing for resistance mutations to this class of drugs.
• HLA-B*5701 status. Those who are positive should not receive ABC.
• Individual preferences
• Anticipated adherence to the regimen

Specific Comorbidities or Other Conditions:

• Cardiovascular disease, hyperlipidemia, renal disease, liver disease, osteopenia/osteoporosis or conditions associated with bone mineral density (BMD) loss, psychiatric illness, neurologic disease, drug abuse or dependency requiring narcotic replacement therapy
• Pregnancy or those with the potential to become pregnant. Clinicians should refer to Table 6b and the latest Perinatal Guidelines for more detailed recommendations on the safety and effectiveness of ARV drugs during conception and throughout pregnancy.
• Coinfections: hepatitis B virus (HBV), hepatitis C virus (HCV), TB

Regimen-Specific Considerations:

• Regimen’s barrier to resistance
• Potential adverse effects
• Known or potential drug interactions with other medications (see Drug-Drug Interactions)
• Convenience (e.g., pill burden, dosing frequency, availability of fixed-dose combination (FDC) formulations, food requirements)
• Cost and access (see Cost Considerations and Antiretroviral Therapy)
Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios (page 1 of 4)

This table provides guidance to clinicians in choosing an initial ARV regimen according to various patient and regimen characteristics and specific clinical scenarios. When more than one scenario applies to a person with HIV, clinicians should review considerations for each relevant scenario and use their clinical judgment to select the most appropriate regimen. This table is intended to guide the initial choice of regimen. However, if a person is doing well on a particular regimen, it is not necessary to switch to another regimen based on the scenarios outlined in this table. Please see Table 9 for additional information regarding the advantages and disadvantages of particular ARV medications.

**Note:** Preliminary data suggest that there may be an increased risk of NTDs in infants born to those who were receiving DTG at the time of conception. Until more information is available, clinicians should review Table 6b for further guidance before prescribing an INSTI to a person of childbearing potential.

<table>
<thead>
<tr>
<th>Patient or Regimen Characteristics</th>
<th>Clinical Scenario</th>
<th>Consideration(s)</th>
<th>Rationale/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD4 cell count &lt;200 cells/mm³</td>
<td>Do Not Use the Following Regimens:</td>
<td>A higher rate of virologic failure has been observed in those with low pretreatment CD4 cell counts.</td>
</tr>
<tr>
<td></td>
<td>• RPV-based regimens</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DRV/r plus RAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV RNA &gt;100,000 copies/mL</td>
<td>Do Not Use the Following Regimens:</td>
<td>Higher rates of virologic failure have been observed in those with high pretreatment HIV RNA levels.</td>
</tr>
<tr>
<td></td>
<td>• RPV-based regimens</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ABC/3TC with EFV or ATV/r</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DRV/r plus RAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLA-B*5701 positive or result unknown</td>
<td>Do not use ABC-containing regimens.</td>
<td>ABC hypersensitivity, a potentially fatal reaction, is highly associated with the presence of the HLA-B*5701 allele.</td>
</tr>
<tr>
<td></td>
<td>ARV should be started before HIV drug resistance results are available (e.g., in a person with acute HIV) or when rapid initiation of ART is warranted</td>
<td>Avoid NNRTI-based regimens. Avoid ABC. Recommended ART Regimens:</td>
<td>Transmitted mutations conferring NNRTI resistance are more likely than mutations associated with PI or INSTI resistance.</td>
</tr>
<tr>
<td></td>
<td>• (DRV/r or DRV/c) plus tenofovir/FTC</td>
<td>• DTG plus tenofovir/FTC</td>
<td>HLA-B*5701 results may not be available rapidly.</td>
</tr>
<tr>
<td></td>
<td>• DTG/ABC/3TC</td>
<td></td>
<td>Transmitted resistance to DRV and DTG is rare, and these drugs have high barriers to resistance.</td>
</tr>
<tr>
<td></td>
<td>• EFV/TDF/FTC</td>
<td></td>
<td>Refer to Table 6b for further guidance before initiating DTG in persons of childbearing potential.</td>
</tr>
<tr>
<td></td>
<td>• EFV/TDF/3TC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EVG/c/TAF/FTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EVG/c/TDF/FTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• RPV/TAF/FTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• RPV/TDF/FTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ART-Specific Characteristics</td>
<td>STR Options as Initial ART Include:</td>
<td>Do not use RPV-based regimens if HIV RNA is &gt;100,000 copies/mL and CD4 cell count is &lt;200/mm³.</td>
</tr>
<tr>
<td></td>
<td>A 1-pill, once-daily regimen is desired</td>
<td>• BIC/TAF/FTC</td>
<td>Do not use DTG/ABC/3TC if patient is HLA-B*5701 positive.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DOR/TDF/3TC</td>
<td>Refer to Table 6b for further guidance before initiating an INSTI in persons of childbearing potential.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DRV/c/TAF/FTC</td>
<td>See Appendix B, Table 8 for ARV dose recommendations in the setting of renal impairment.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DTG/ABC/3TC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EFV/TDF/FTC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EFV/TDF/3TC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EVG/c/TAF/FTC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EVG/c/TDF/FTC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RPV/TAF/FTC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RPV/TDF/FTC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Food effects</td>
<td>Regimens that Can be Taken Without Regard to Food:</td>
<td>Oral bioavailability of these regimens is not significantly affected by food.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• BIC-, DOR-, DTG-, or RAL-based regimens</td>
<td>Refer to Table 6b for further guidance before initiating an INSTI in persons of childbearing potential.</td>
</tr>
<tr>
<td>Patient or Regimen Characteristics</td>
<td>Clinical Scenario</td>
<td>Consideration(s)</td>
<td>Rationale/Comments</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ART-Specific Characteristics, continued</td>
<td>Food effects, continued</td>
<td>Regimens that Should Be Taken with Food:</td>
<td>Food improves absorption of these regimens. RPV-containing regimens should be taken with at least 390 calories of food.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ATV/r- or ATV/c-based regimens</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DRV/r- or DRV/c-based regimens</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EVG/c/TAF/FTC&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EVG/c/TDF/FTC&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RPV-based regimens</td>
<td>Food increases EFV absorption and may increase CNS side effects.</td>
</tr>
<tr>
<td>Presence of Other Conditions</td>
<td>Chronic kidney disease (defined as CrCl &lt;60 mL/min)</td>
<td>Avoid TDF unless the patient has ESRD. Use ABC or TAF.</td>
<td>TDF has been associated with proximal renal tubulopathy. Higher rates of renal dysfunction have been reported in patients using TDF in conjunction with RTV-containing regimens.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABC may be used if patient is HLA-B&lt;sup&gt;*5701&lt;/sup&gt; negative. If HIV RNA &gt;100,000 copies/mL, do not use ABC/3TC plus (EFV or ATV/r).</td>
<td>An adjusted dose of TDF can be used in patients with ESRD or in those who are on hemodialysis. Refer to Appendix B, Table 8 for specific dosing recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TAF may be used if CrCl &gt;30 mL/min.</td>
<td>TAF has less impact on renal function and lower rates of proteinuria than TDF.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consider avoiding ATV.</td>
<td>ATV has been associated with chronic kidney disease in some observational studies.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ART Options When ABC, TAF or TDF Cannot be Used:</td>
<td>ABC has not been associated with renal dysfunction.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DTG plus 3TC</td>
<td>Refer to Appendix B, Table 8 for specific dosing recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DRV/r plus 3TC</td>
<td>Patients with cirrhosis should be carefully evaluated by an expert in advanced liver disease.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DRV/r plus RAL (if CD4 cell count &gt;200 cells/mm&lt;sup&gt;3&lt;/sup&gt; and HIV RNA &lt;100,000 copies/mL)</td>
<td>Patients with cirrhosis should be carefully evaluated by an expert in advanced liver disease.</td>
</tr>
<tr>
<td>Liver disease with cirrhosis</td>
<td></td>
<td>Some ARVs are contraindicated or may require dosage modification in patients with Child-Pugh class B or C disease.</td>
<td>TDF is associated with decreases in BMD along with renal tubulopathy, urine phosphate wasting, and resultant osteomalacia. TAF and ABC are associated with smaller declines in BMD than TDF.</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td></td>
<td>Avoid TDF.</td>
<td>Refer to Appendix B, Table 8 for specific dosing recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use ABC or TAF.</td>
<td>Patients with cirrhosis should be carefully evaluated by an expert in advanced liver disease.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABC may be used if patient is HLA-B&lt;sup&gt;*5701&lt;/sup&gt; negative. If HIV RNA &gt;100,000 copies/mL, do not use ABC/3TC plus (EFV or ATV/r).</td>
<td>TDF is associated with decreases in BMD along with renal tubulopathy, urine phosphate wasting, and resultant osteomalacia. TAF and ABC are associated with smaller declines in BMD than TDF.</td>
</tr>
<tr>
<td>Psychiatric illnesses</td>
<td>Consider avoiding EFV- and RPV-based regimens.</td>
<td>Some ARVs are contraindicated and some psychiatric medications need dose adjustments when coadministered with certain ARVs.</td>
<td>EFV and RPV can exacerbate psychiatric symptoms and may be associated with suicidality. INSTIs have been associated with adverse neuropsychiatric effects in some retrospective cohort studies and case series.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patients on INSTI-based regimens who have pre-existing psychiatric conditions should be closely monitored.</td>
<td>See the drug-drug interaction tables (Tables 19a, 19b, and 19d) for dosing recommendations when drugs used for psychiatric illnesses are used with certain ARVs.</td>
</tr>
</tbody>
</table>
### Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios

<table>
<thead>
<tr>
<th>Patient or Regimen Characteristics</th>
<th>Clinical Scenario</th>
<th>Consideration(s)</th>
<th>Rationale/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of Other Conditions, continued</td>
<td>HAD</td>
<td>Avoid EFV-based regimens if possible. Favor DTG- or DRV-based regimens.</td>
<td>EFV-related neuropsychiatric effects may confound assessment of ART’s beneficial effects on improvement of HAD-related symptoms. There is a theoretical CNS penetration advantage of DTG- or DRV-based regimens.</td>
</tr>
<tr>
<td>Medication-assisted treatment for opioid dependence</td>
<td>Opioid withdrawal may occur when EFV is initiated in patients who are on a stable dose of methadone.</td>
<td>Clinical monitoring is recommended, as medications used to treat opioid dependence may need to be adjusted in some patients.</td>
<td>EFV reduces methadone concentrations and may lead to withdrawal symptoms. See the drug-drug interaction tables (Tables 19a, 19b, and 19d) for dosing recommendations.</td>
</tr>
<tr>
<td>High cardiac risk</td>
<td>Consider avoiding ABC- and LPV/r-based regimens. If a boosted PI is the desired option, an ATV-based regimen may have advantages over a DRV-based regimen. BIC-, DOR-, DTG-, RAL-, or RPV-based regimens may be considered for those with high cardiac risk.</td>
<td>An increased CV risk with ABC has been observed in some studies. Observational cohort studies reported an association between some PIs (DRV, IDV, FPV, and LPV/r) and an increased risk of CV events; this risk has not been seen with ATV (see text). Further study is needed. BIC-, DOR-, DTG-, RAL- or RPV-based regimens have more favorable lipid profiles than other regimens, although evidence on whether this improves CV outcomes is lacking. Refer to Table 6b for further guidance before initiating an INSTI in persons of childbearing potential.</td>
<td></td>
</tr>
<tr>
<td>Cardiac QTc interval prolongation</td>
<td>Consider avoiding EFV- or RPV-based regimens if patient is taking other medications with known risk of Torsades de Pointes, or in patients at higher risk of Torsades de Pointes.</td>
<td>High EFV or RPV concentrations may cause QT prolongation.</td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>The Following ARV Drugs Have Been Associated with Dyslipidemia: PIf or PIf/c EFV EVG/c BIC, DOR, DTG, RAL, and RPV have fewer lipid effects.</td>
<td>TDF has been associated with lower lipid levels than ABC or TAF. Refer to Table 6b for further guidance before initiating an INSTI in persons of childbearing potential.</td>
<td></td>
</tr>
<tr>
<td>Patients with history of poor adherence to non-ARV medications or inconsistent engagement in care</td>
<td>Consider using regimens with a boosted PI or DTG. BIC also has a high barrier to resistance, but there is currently no data on its efficacy in this population.</td>
<td>These regimens have a high genetic barrier to resistance. Refer to Table 6b for further guidance before initiating an INSTI in persons of childbearing potential.</td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios  (page 4 of 4)

<table>
<thead>
<tr>
<th>Patient or Regimen Characteristics</th>
<th>Clinical Scenario</th>
<th>Consideration(s)</th>
<th>Rationale/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Presence of Other Conditions, continued</strong></td>
<td><strong>Pregnancy</strong></td>
<td>Until more information is available, <strong>do not initiate a DTG-based regimen for those who are pregnant and within 12 weeks post-conception, because preliminary data suggest that there is an increased risk of NTDs in infants born to those who were receiving DTG at the time of conception</strong>.6,7</td>
<td>Refer to Table 6b and the Perinatal Guidelines for further guidance on ARV use during pregnancy.</td>
</tr>
<tr>
<td></td>
<td><strong>Patients of childbearing potential who are planning to become pregnant or who are sexually active and not using effective contraception</strong></td>
<td>Until more information is available, <strong>do not initiate a DTG-based regimen in these patients</strong>, because preliminary data suggest that there is an increased risk of NTDs in infants born to those who were receiving DTG at the time of conception.6,7</td>
<td>Refer to Table 6b for further guidance before initiating an INSTI.</td>
</tr>
<tr>
<td><strong>Presence of Coinfections</strong></td>
<td><strong>HBV infection</strong></td>
<td>Use TDF or TAF, with FTC or 3TC, whenever possible.</td>
<td>TDF, TAF, FTC, and 3TC are active against both HIV and HBV. 3TC- or FTC-associated HBV mutations can emerge rapidly when these drugs are used without another drug that is active against HBV.</td>
</tr>
<tr>
<td></td>
<td><strong>HCV treatment required</strong></td>
<td>Refer to recommendations in HCV/HIV Coinfection, with special attention to potential interactions between ARV drugs and HCV drugs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Treating TB disease with rifamycins</strong></td>
<td><strong>TAF and BIC are not recommended with any rifamycin-containing regimen.</strong></td>
<td>Rifamycins may significantly reduce TAF and BIC exposures.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If Rifampin is Used: • <strong>The following are not recommended:</strong> PI/c or PI/r, BIC, EVG, DOR, RPV, or TAF; • EFV can be used without dose adjustment.</td>
<td>Rifampin is a strong inducer of CYP3A4 and UGT1A1 enzymes, causing significant decreases in concentrations of PIs, INSTIs, DOR, and RPV. Rifampin has a less significant effect on EFV concentration than on the concentrations of other NNRTIs, PIs, and INSTIs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• If RAL is used, increase RAL dose to 800 mg BID. Do not use once-daily RAL.</td>
<td>Refer to Table 6b for further guidance before initiating an INSTI in persons of childbearing potential.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Use DTG at 50 mg BID dose only in patients without selected INSTI mutations (refer to product label).</td>
<td>See the drug-drug interaction tables (Tables 19a, 19b, 19c, 19d and 19e) and TB/HIV Coinfection for information on ARV use with rifamycins.</td>
</tr>
</tbody>
</table>

* TAF and TDF are two approved forms of tenofovir. TAF has fewer bone and kidney toxicities than TDF, whereas TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs.

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/ cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; BID = twice daily; BMD = bone mineral density; COBI = cobicistat; CD4 = CD4 T lymphocyte; CNS = central nervous system; CrCl = creatinine clearance; CV = cardiovascular; CYP = cytochrome P; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FPV = fosamprenavir; FTC = emtricitabine; HAD = HIV-associated dementia; HBV = hepatitis B virus; HCV = hepatitis C virus; HLA = human leukocyte antigen; IDV = indinavir; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; PI = protease inhibitor; PI/c = cobicistat-boosted protease inhibitor; PI/r = ritonavir-boosted protease inhibitor RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; STR = single-tablet regimen; TAF = tenofovir alafenamide; TB = tuberculosis; TDF = tenofovir disoproxil fumarate; UGT = uridine diphosphate glucuronosyltransferase.
Characteristics of Antiretroviral Drugs Recommended for Initial Therapy

The following sections provide detailed information regarding the characteristics, clinical trial results, adverse effects profile, and the Panel’s recommendations for ARV drugs that are recommended as initial therapy for persons with HIV.

Dual-Nucleoside Reverse Transcriptase Inhibitor Options as Part of Initial Combination Therapy

Table 8a. Characteristics of Dual-Nucleoside Reverse Transcriptase Inhibitor Options Recommended for Antiretroviral Therapy-Naive Patients

<table>
<thead>
<tr>
<th></th>
<th>ABC/3TC</th>
<th>TAF/FTC</th>
<th>TDF/FTC</th>
<th>TDF/3TC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing Frequency</strong></td>
<td>Once daily</td>
<td>Once daily</td>
<td>Once daily</td>
<td>Once daily</td>
</tr>
<tr>
<td><strong>Available Coformulations for ART-Naive Patients</strong></td>
<td>• ABC/3TC</td>
<td>• TAF 25 mg/FTC</td>
<td>• TDF/FTC</td>
<td>• TDF/3TC</td>
</tr>
<tr>
<td></td>
<td>• DTG/ABC/3TC</td>
<td>• BIC/TAF 25 mg/FTC</td>
<td>• EFV/TDF/FTC</td>
<td>• DOR/TDF/3TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DRV/c/TAF 10 mg/FTC</td>
<td>• EVG/c/TDF 10 mg/FTC</td>
<td>• EFV 600 mg/TDF/3TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EVG/c/TAF 10 mg/FTC</td>
<td>• RPV/TDF/FTC</td>
<td>• EFV 400 mg/TDF/3TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• RPV/TAF 25 mg/FTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td><strong>ABC:</strong></td>
<td>TAF:</td>
<td>TDF:</td>
<td>TDF:</td>
</tr>
<tr>
<td></td>
<td>• HSR to ABC is associated with the presence of HLA-B*5701 allele</td>
<td>• Renal insufficiency, proximal renal tubulopathy (less frequent than with TDF)</td>
<td>• Renal insufficiency, proximal renal tubulopathy</td>
<td>• Renal insufficiency, proximal renal tubulopathy</td>
</tr>
<tr>
<td></td>
<td>• Increase in CV events is associated with ABC use in some, but not all, cohort studies</td>
<td>• Decrease in BMD (less than with TDF; similar to ABC)</td>
<td>• Decrease in BMD</td>
<td>• Decrease in BMD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Renal and bone toxicity are exacerbated by pharmacologic boosters</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Renal and bone toxicity are exacerbated by pharmacologic boosters</td>
</tr>
<tr>
<td></td>
<td>FTA: Nail pigmentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3TC: No significant adverse effects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Considerations</strong></td>
<td>• Perform HLA-B*5701 testing before initiating ABC; if result is positive, do not start ABC and add ABC to allergy list</td>
<td>Also used for HBV treatment. Discontinuation may precipitate flair of HBV.</td>
<td>See Appendix B, Table 8 for dose recommendations in patients with renal insufficiency.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• If HIV RNA &gt;100,000 copies/mL, use only with DTG</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; BIC = bictegravir; BMD = bone mineral density; CV = cardiovascular; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/copestastat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/copestastat; FTC = emtricitabine; HBV = hepatitis B virus; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
Summary

FDA-approved NRTIs include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), ABC, TDF, TAF, 3TC, and FTC. Older NRTIs (ZDV, d4T, ddI) are no longer recommended for use in clinical practice in the United States due to high rates of serious toxicities, including bone marrow suppression from ZDV use. Other toxicities that mainly occur due to mitochondrial toxicity may lead to myopathy, peripheral neuropathy, hepatic steatosis, lactic acidosis, and lipoatrophy. The incidence of these complications is much lower with 3TC, FTC, ABC, TDF, and TAF than with older NRTIs.26,27

ABC/3TC, TAF/FTC, TDF/3TC, and TDF/FTC are NRTI combinations that are recommended for use as components of initial therapy. Table 6a provides recommendations and ratings for the individual regimens. These recommendations are based on the virologic potency and durability, short- and long-term toxicity, and dosing convenience of these drugs. TAF and TDF are two approved forms of tenofovir. TDF has been associated with bone and kidney toxicities, especially when used with a pharmacologic booster.28 TAF is less likely to cause kidney and bone toxicities than TDF. TDF is associated with lower lipid levels than TAF. Safety, cost, and access are among the factors to consider when choosing between these drugs. ABC/3TC and TDF/3TC are available as generic formulations.

Clinical Trials Comparing Nucleoside Reverse Transcriptase Inhibitors

Abacavir/Lamivudine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine

Several randomized controlled trials in ART-naive participants compared ABC/3TC to TDF/FTC, each administered in combination with a third ARV drug10,29,30 (see also the discussion in the DTG section).31

• The ACTG 5202 study, a randomized controlled trial in >1,800 participants, evaluated the efficacy and safety of ABC/3TC and TDF/FTC when each was used in combination with either EFV or ATV/r. In patients with baseline HIV RNA ≥100,00 copies/mL, there was a significantly shorter time to virologic failure with ABC/3TC than with TDF/FTC regardless of whether the third active drug was EFV or ATV/r.10 In the HEAT study, 688 participants received ABC/3TC or TDF/FTC in combination with once-daily LPV/r. Virologic efficacy was similar in the two study arms, including in a subgroup with HIV RNA ≥100,000 copies/mL.30

• The ASSERT study compared open-label ABC/3TC with TDF/FTC in 385 HLA-B*5701–negative, ART-naive patients; all participants also received EFV. The primary study endpoint was renal safety of the regimens. At week 48, the proportion of participants with HIV RNA <50 copies/mL was lower among ABC/3TC-treated participants than among TDF/FTC-treated participants.29

Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate

• Two randomized double-blind Phase 3 clinical trials compared the safety and efficacy of EVG/c/TDF/FTC and EVG/c/TAF/FTC in 1,733 ART-naive adults with estimated glomerular filtration rate (eGFR) ≥50 mL/min.

  • TAF/FTC was virologically noninferior to TDF/FTC at week 48 (92% vs. 90% of participants achieved plasma HIV RNA <50 copies/mL, respectively),32 but TAF/FTC was superior to TDF/FTC at week 144 (84.2% vs. 80%), largely driven by a higher rate of treatment discontinuation in the TDF arm.33

  • Participants in the TAF arm had significantly smaller reductions in BMD at the spine and hip than those in the TDF arm through 144 weeks.33 They also had less pronounced changes in eGFR and renal biomarkers and fewer clinically significant renal events through week 96.34 Conversely, levels of fasting low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides increased more in the TAF group than in the TDF group at 96 weeks, with no change in total cholesterol to HDL ratio.35
Two randomized studies have compared the safety and efficacy of TAF/FTC to TDF/FTC each administered in combination with boosted DRV in ART-naive subjects:

- A Phase 2 study of coformulated DRV/c plus TAF/FTC versus DRV/c plus TDF/FTC demonstrated similar virologic suppression rates in both arms (75% vs. 74%) in treatment-naive patients. In the TAF arm, fewer participants developed proteinuria. Changes in BMD were also less pronounced among these participants.

- The AMBER study randomized ART-naive participants to receive either coformulated DRV/c/TAF/FTC or DRV/c plus TDF/FTC. At 48 weeks, HIV RNA <50 copies/mL was achieved in 91% of the DRV/c/TAF/FTC participants versus 88% of the DRV/c plus TDF/FTC participants. Participants in the TAF/FTC arm showed less decline in hip and spine BMD and eGFR than participants in the TDF/FTC arm.

- One analysis evaluated data from 11 randomized trials that compared the virologic efficacy, frequency of renal events, and bone density changes associated with the use of TDF or TAF when either drug was taken with or without PK boosters (RTV or COBI). There were no significant differences between unboosted TDF and TAF in terms of virologic efficacy or in the number of participants who discontinued treatment due to renal or bone adverse events or fractures. However, bone- and renal-related toxicities were more pronounced when TDF was used in combination with RTV or COBI.

- To assess the ability of TAF to maintain HIV and HBV suppression, 72 patients with HIV/HBV coinfection who had HIV RNA <50 copies/mL and HBV DNA <9 log10 IU/mL on a stable regimen were switched to EVG/c/TAF/FTC. In this study, 96% of participants were on a TDF/FTC-containing regimen prior to the switch. Key results of the study showed that:
  - Those who switched to EVG/c/TAF/FTC maintained HIV suppression: 94.4% and 91.7% of participants at 24 and 48 weeks, respectively. At 24 and 48 weeks, 86.1% and 91.7% of participants had HBV DNA <29 log10 IU/mL.
  - Decreases in markers of proximal tubular proteinuria and biomarkers of bone turnover were seen in those who switched to EVG/c/TAF/FTC.

**Dual-Nucleoside Reverse Transcriptase Inhibitor Choices** (In alphabetical order)

**Abacavir/Lamivudine (ABC/3TC)**

ABC plus 3TC has been studied in combination with EFV, several PIs, and DTG in ART-naive patients.

**Adverse Effects**

**Hypersensitivity Reactions:**

- Clinically suspected hypersensitivity reactions (HSRs) were observed in 5% to 8% of individuals who started ABC in clinical trials conducted before the use of HLA-B*5701 testing. The risk of HSRs is highly associated with the presence of the HLA-B*5701 allele; approximately 50% of HLA-B*5701–positive patients will have an ABC-related HSR if given this drug. HLA-B*5701 testing should be done if the use of ABC is being considered. In a patient who tests positive for HLA-B*5701, ABC should not be given and ABC hypersensitivity should be noted on the allergy list. Patients who are HLA-B*5701 negative are far less likely to experience an HSR, but they should be counseled about the symptoms of the reaction. Patients who discontinue ABC because of a suspected HSR should never be rechallenged, regardless of their HLA-B*5701 status.

**Cardiovascular Risk:**

- An association between ABC use and myocardial infarction (MI) was first reported in the D:A:D study. This large, multinational, observational study group found that recent (i.e., within 6 months) or current use of ABC was associated with an increased risk of MI, particularly in patients with pre-existing cardiac risk factors.
• Since the D:A:D report, several studies have evaluated the relationship between ABC therapy and cardiovascular events. Some studies have found an association.45-51 Others, including an FDA meta-analysis of 26 randomized clinical trials that evaluated ABC, have not.18,52-55

• An analysis of data from NA-ACCORD found that use of ABC in the previous 6 months was associated with an increased risk of both type 1 and type 2 MIs after adjusting for cardiovascular disease risk factors.56

• No consensus has been reached on the association between ABC use and MI risk or the mechanism for such an association.

Other Factors and Considerations:

• ABC/3TC is available as a coformulated tablet and as a coformulated STR with DTG.

• ABC and 3TC are available separately and as a coformulated tablet in generic tablet formulations.

• ABC does not cause renal dysfunction and can be used instead of TDF in patients with underlying renal dysfunction or in those who are at high risk for renal effects. No dose adjustment is required in patients with renal dysfunction.

The Panel’s Recommendations:

• ABC should only be prescribed for patients who are HLA-B*5701 negative.

• On the basis of clinical trial safety and efficacy data, experience in clinical practice, and the availability of DTG/ABC/3TC as an FDC, the Panel classifies DTG/ABC/3TC as a Recommended Initial Regimen for Most People with HIV (AI) (see the discussion of DTG in this section regarding the clinical efficacy data for ABC/3TC plus DTG).

• ABC/3TC use with EFV, ATV/r, ATV/c, DRV/c, DRV/r, or RAL is only recommended for patients with pretreatment HIV RNA levels <100,000 copies/mL. See Table 6a for more detailed recommendations on the use of ABC/3TC with these drugs.

• ABC should be used with caution or avoided in patients with known high cardiovascular risk.

Tenofovir Alafenamide/Emtricitabine (TAF/FTC)

TAF, an oral prodrug of tenofovir (TFV), is hydrolyzed to TFV in plasma and then converted to TFV-diphosphate (TFV-DP) intracellularly, where it exerts its activity as an NRTI. Unlike TDF, which readily converts to TFV in plasma after oral absorption, TAF remains relatively stable in plasma, resulting in lower plasma and higher intracellular TFV concentrations. After oral administration, TAF 25 mg resulted in plasma TFV concentrations that were 90% lower than those seen with TDF 300 mg. Intracellular TFV-DP concentrations, however, were substantially higher with TAF.

Adverse Effects

Renal and Bone Effects:

• The potential for adverse kidney and bone effects is lower with TAF than with TDF. In randomized controlled trials that compared TAF and TDF in treatment-naive or virologically suppressed patients, TAF had more favorable effects on renal biomarkers and bone density than TDF (described below).

Lipid Effects:

• In randomized controlled trials in ART-naive patients, as well as in switch studies (described below), levels of LDL and HDL cholesterol and triglycerides were higher in patients receiving TAF than in patients receiving TDF. However, total cholesterol to HDL ratios did not differ between patients receiving TAF and TDF. The clinical significance of this finding is not clear.32,57,58
Other Factors and Considerations:

- TAF/FTC is available in FDCs with DRV/c, EVG/c or RPV, allowing the regimens to be administered as a single pill taken once daily with food.

- In Phase 3 randomized trials, BIC/TAF/FTC was comparable to DTG/ABC/3TC and to DTG plus TAF/FTC (see the INSTI section below).

- TAF-containing regimens are approved for patients with eGFR ≥30 mL/min. Renal function, urine glucose, and urine protein should be assessed before initiating treatment with TAF, and these assessments should be repeated periodically during treatment. EVG/c/FTC/TAF was safe and effective in a single-arm switch study that was conducted in patients on hemodialysis with eGFRs <15 mL/min.59

- Both TAF and FTC are active against HBV. In patients with HIV/HBV coinfection, TAF/FTC may be used as the NRTI pair in an ART regimen because these drugs have activity against both viruses (see HBV/HIV Coinfection).38

The Panel’s Recommendation:

- On the basis of clinical trial safety and efficacy data, supportive bioequivalence data,60 and its availability as a component of various FDCs, the Panel considers TAF/FTC a recommended NRTI combination for initial ART in most persons with HIV when prescribed with BIC, DTG, and RAL.

Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) and Tenofovir Disoproxil Fumarate/Lamivudine (TDF/3TC)

TDF, with either 3TC or FTC, has been studied in combination with DOR, EFV, RPV, several boosted PIs, EVG/c, RAL, and DTG in randomized clinical trials.61,62-70 In a 10-day, open-label, randomized monotherapy trial that was not powered to find a difference between the arms, FTC 200 mg once daily demonstrated a viral load reduction of 1.7 log10 from baseline, compared with a reduction of 1.5 log10 from baseline for 3TC 150 mg twice daily.71

In a meta-analysis of 12 trials, no significant difference in treatment success was found between 3TC and FTC.72 In the ATHENA cohort, virologic efficacy of TDF/FTC was compared to TDF/3TC when either was combined with an NNRTI (EFV or NVP)73 or with a boosted PI.74 TDF/3TC was associated with higher rates of virologic failure than TDF/FTC in the NNRTI analysis; however, it is worth noting that the people in this cohort who were taking 3TC generally had higher viral loads, lower CD4 cell counts, and were more likely to be using injection drugs at the start of the study than people who were taking FTC.73

There was no difference in the rates of virologic failure in people who were taking TDF/FTC and people who were taking TDF/3TC when these drug combinations were used with a boosted PI74. A retrospective analysis of an Italian national database found that viral resistance was more common with TDF/3TC than with TDF/FTC, but this was not observed in clinical trials.75

Adverse Effects

Renal Effects:

- New onset or worsening renal impairment has been associated with TDF use.76,77 Risk factors may include advanced HIV disease, longer treatment history, low body weight (especially in females)78 and pre-existing renal impairment.79 Concomitant use of a PK-enhanced regimen (with a PI or EVG) can increase TDF concentrations; studies have suggested that there is a greater risk of renal dysfunction when TDF is used in these regimens. As previously noted, adverse effects on renal biomarkers such as proteinurias, especially tubular proteinuria, were more frequent with TDF than with TAF.77,79-83

- Adverse renal outcomes are more likely when TDF/FTC is coadministered with PK boosters (RTV or COBI). A meta-analysis of randomized trials found that discontinuation due to renal adverse events is more frequent in people who take TDF/FTC with PK boosting.28
**Bone Effects:**

- While initiation of all NRTI-containing regimens has been associated with a decrease in BMD, the loss of BMD is greater with TDF-containing regimens. For example, in two randomized studies that compared TDF/FTC with ABC/3TC, participants who received TDF/FTC experienced a significantly greater decline in BMD than ABC/3TC-treated participants.⁸⁴,⁸⁵ BMD generally stabilizes following an early decline after ART initiation. Loss of BMD with TDF is also greater than with TAF (see above).

- Cases of osteomalacia associated with proximal renal tubulopathy have been reported with the use of TDF.⁸⁶

- **Adverse bone outcomes are more likely when TDF/FTC is coadministered with PK boosters (RTV or COBI).** A meta-analysis of randomized trials found that fractures and discontinuation due to bone adverse events occur more frequently among patients who take TDF/FTC with PK boosting.²⁸

**Other Factors and Considerations:**

- TDF/FTC is available in FDCs with EFV, EVG/c, and RPV, allowing the regimens to be administered as a single pill taken once daily.

- TDF/3TC is available in FDCs with DOR 100 mg, EFV 600 mg, and EFV 400 mg.

- Renal function, urine glucose, and urine protein should be assessed before initiating treatment with TDF and periodically during treatment (see Laboratory Testing for Initial Assessment and Monitoring). In patients who have pre-existing renal insufficiency (creatinine clearance [CrCl] <60 mL/min),⁸⁷ use of TDF should generally be avoided. If TDF is used, a dose adjustment is required if the patient’s CrCl falls below 50 mL/min (see Appendix B, Table 8 for dose recommendations).

- TDF, FTC, and 3TC are active against HBV. In patients with HIV/HBV coinfection, TDF/FTC or TDF/3TC may be used as the NRTI pair of the ART regimen because these drugs have activity against both viruses (see HBV/HIV Coinfection).

**The Panel’s Recommendations:**

- On the basis of clinical trial safety and efficacy data, long-term experience in clinical practice, and the combination’s availability as a component of FDC drugs, the Panel considers TDF/FTC and TDF/3TC as recommended NRTI combinations for initial ART in most persons with HIV when combined with DTG or RAL. See Table 6a for recommendations regarding use of TDF/FTC with other drugs.

- TDF should be used with caution or avoided in patients with renal disease and osteoporosis.

- **Specific attention should be given to renal and bone safety monitoring when TDF is used, especially with PK boosters. Boosters should be avoided when possible in patients taking TDF.**
Integrase Strand Transfer Inhibitor–Based Regimens

Table 8b. Characteristics of Integrase Strand Transfer Inhibitors That Are Recommended for Antiretroviral Therapy-Naive Patients

Note: Preliminary data suggest that there may be an increased risk of NTDs in infants born to those who were receiving DTG at the time of conception. Until more information is available:

- Pregnancy testing should be performed for those of childbearing potential prior to initiation of ART.
- DTG is not recommended for ART-naive individuals:
  - Who are pregnant and within 12 weeks post-conception, or
  - Who are of childbearing potential and who are planning to become pregnant or who are sexually active and not using effective contraception.

Clinicians should refer to Table 6b for further guidance before initiating an INSTI.

<table>
<thead>
<tr>
<th></th>
<th>BIC</th>
<th>DTG</th>
<th>EVG</th>
<th>RAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing Frequency</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIC/TAF/FTC</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>DTG/ABC/3TC</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>STR Available for ART-Naive Patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIC/TAF/FTC</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>DTG/ABC/3TC</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Available as a Single-Drug Tablet</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Approved for ART-Experienced Patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Virologic Efficacy Against EVG- or RAL-Resistant HIV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In vitro data indicate activity, but no clinical trial data are available</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea, diarrhea (GI disturbance greater with EVG/c), headache, insomnia. Depression and suicidality are rare, occurring primarily in patients with pre-existing psychiatric conditions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↑ CPK (4%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity, hepatotoxicity, ↑ CPK, myositis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↑ TG, ↑ LDL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↑ CPK, myopathy, hypersensitivity, SJS/TEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CYP3A4 Drug-Drug Interactions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A4 substrate</td>
<td>CYP3A4 substrate (minor)</td>
<td>EVG is a CYP3A4 substrate; COBI is a CYP3A4 inhibitor</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td><strong>Chelation with Polyvalent Cation Supplements and Antacids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral absorption of all INSTIs may be reduced by polyvalent cations. See Table 19d for recommendations regarding dosing separation of INSTIs and these drugs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Key Potential Drug Interactions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UGT1A1 substrate, OAT1 and MATE2 inhibitor</td>
<td>p-gp substrate, UGT1A1 substrate</td>
<td>EVG is a UGT1A1 substrate; COBI is a p-gp inhibitor</td>
<td>UGT1A1 substrate</td>
<td></td>
</tr>
</tbody>
</table>

Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; BIC = bictegravir; BID = twice daily; COBI = cobicistat; CPK = creatine phosphokinase; CYP = cytochrome P; DRM = drug resistance mutation; DTG = dolutegravir; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; GI = gastrointestinal; INSTI = integrase strand transfer inhibitor; LDL = low density lipoprotein; MATE = multidrug and toxic compound extrusion; NNRTI = non-nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; OAT = organic anionic transporter; p-gp = p-glycoprotein; PI = protease inhibitor; PI/r = ritonavir-boosted protease inhibitor; RAL = raltegravir; SJS/TEN = Stevens Johnson Syndrome/toxic epidermal necrolysis; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TG = triglyceride; UGT = uridine diphosphate glucuronosyltransferase.
**Summary**

Four INSTIs—BIC, DTG, EVG, and RAL—are approved for use in ART-naive patients with HIV. All INSTIs are generally well tolerated, though there are reports of insomnia in some patients. Depression and suicidal ideation, primarily in patients with a history of psychiatric illnesses, have rarely been reported in patients receiving INSTI-based regimens. BIC, DTG, and EVG are available as components of STRs—BIC is coformulated with TAF/FTC, DTG is coformulated with ABC/3TC, and EVG is coformulated with a PK enhancer (COBI) and either TAF/FTC or TDF/FTC. The Panel classifies the three unboosted INSTI-based regimens (BIC, DTG, and RAL) as Recommended Initial Regimens for Most People with HIV. Among the INSTI-based regimens, RAL-containing regimens have the longest clinical experience, and they have been shown to have durable virologic efficacy; however, they have a higher pill burden than BIC- and DTG-containing regimens. EVG and RAL have lower barriers to resistance than BIC and DTG. In clinical trials of ART-naive patients who received BIC or DTG plus two NRTIs, resistance was not seen at virologic failure. Because of its high barrier to resistance, DTG may be considered for patients who must start ART before resistance test results are available (e.g., during acute HIV infection and in the setting of certain opportunistic infections). EVG-based regimens are now considered Recommended Initial Regimens in Certain Clinical Situations, because they require boosting with COBI, which results in a greater potential for interaction with concomitant medications.

Preliminary data from an observational study in Botswana suggest that there may be an increased risk of NTDs in infants born to those who were receiving DTG at the time of conception. Until more information is available, DTG-based regimens are not recommended for use in ART-naive patients who are pregnant and within 12 weeks post-conception. These regimens also should not be used in those of childbearing potential who are sexually active and not using effective contraception or who are planning to become pregnant.

It is unclear whether DTG is the only INSTI with the potential to cause NTDs, or if other INSTIs also carry this risk (i.e., a class effect). Table 6b provides recommendations on the use of INSTIs in those who are pregnant or of childbearing potential.

**Integrase Strand Transfer Inhibitors Recommended as Part of an Initial Regimen for Most People with HIV**

**Bictegravir (BIC)**

BIC is an INSTI that is approved by the FDA for initial therapy in adults with HIV as a component of a single-tablet, once-daily regimen with TAF and FTC.

**Efficacy in Clinical Trials:**

- The efficacy of BIC in ART-naive adults has been evaluated in two large Phase 3 randomized double-blind clinical trials that compared BIC to DTG administered in combination with two NRTIs. The primary efficacy endpoint was the proportion of participants with plasma HIV RNA <50 copies/mL at week 48.
  - The GS-US-380-1490 trial randomized participants 1:1 to receive either BIC/TAF/FTC or DTG with coformulated TAF/FTC. Both regimens were given once daily. At week 48, 89% of participants in the BIC arm and 93% of those in the DTG arm achieved HIV RNA <50 copies/mL ($P = 0.12$).
  - The GS-US-380-1489 trial randomized participants 1:1 to receive BIC/TAF/FTC or coformulated DTG/ABC/3TC once daily. At week 48, 92.4% of participants in the BIC/TAF/FTC arm and 93% of those in the DTG/ABC/3TC arm achieved HIV RNA <50 copies/mL ($P = 0.78$).

**Adverse Effects:**

- BIC is generally well tolerated. In clinical trials, the most commonly reported adverse reactions of all grades with an incidence $\geq 5\%$ included diarrhea, nausea, and headache.
Other Factors and Considerations:

- BIC is a CYP3A4 substrate and a UGT1A1 substrate, and its metabolism may be affected by concomitant use of CYP3A4 and UGT1A1 inducers or inhibitors. Rifampin or other rifamycins may decrease BIC or TAF concentrations, which may result in a loss of therapeutic effect. For patients who require rifamycins, BIC/FTC/TAF should not be used. Use of certain anticonvulsants and St. John’s wort should also be avoided.88

- BIC is an inhibitor of the drug transporters OAT2 and MATE1, which may lead to increased concentrations of drugs that are substrates of these transporters. For this reason, dofetilide is contraindicated with BIC/TAF/FTC.

- BIC is not a CYP3A4 inducer or inhibitor; thus, unlike EVG/c, it is unlikely to affect the metabolism of medications that are CYP3A4 substrates.

- Like other INSTIs, oral absorption of BIC may be reduced when BIC is coadministered with polyvalent cations (e.g., aluminum-, magnesium-, or calcium-containing antacids, or calcium or iron supplements). See Table 19d for dosing recommendations when using BIC with these products.

- BIC decreases tubular secretion of creatinine without affecting glomerular function. Increases in serum creatinine are typically observed within the first 4 weeks (with a median increase of 0.10 mg/dL after 48 weeks). This effect on creatinine secretion is similar to that seen with other medications used in people with HIV, including DTG and COBI.

- Treatment-emergent mutations that confer BIC resistance have not yet been reported in people receiving BIC for initial therapy. BIC has not been studied in people with prior INSTI failure or INSTI-related resistance mutations, and BIC should not be used in these individuals until more data are available.

- BIC and DTG share a similar chemical structure. It is unclear whether DTG is the only INSTI with the potential to cause NTDs or if other INSTIs also carry this risk.

The Panel’s Recommendation:

- On the basis of clinical trial data, the Panel categorizes the combination of BIC/TAF/FTC administered once daily as a Recommended Initial Regimen for Most People with HIV (AI).

- Because there are no safety data for the use of BIC around the time of conception to guide evidence-based recommendations, a similar approach to the one outlined for DTG should be discussed before considering the use of BIC-containing ART in those of childbearing potential. The use of BIC-containing ART is not recommended during pregnancy.

**Dolutegravir (DTG)**

DTG is an INSTI with a higher barrier to resistance than EVG or RAL. In ART-naive patients, DTG plus two NRTIs demonstrated high efficacy in achieving HIV suppression. It is given once daily, with or without food. Preliminary data from Botswana suggest that there may be an increased risk of NTDs in infants born to women who were receiving DTG at the time of conception.64 More detailed discussions of this potential risk and recommendations for the use of this drug are found below and in Table 6b.

**Efficacy in Clinical Trials**

The efficacy of DTG in ART-naive patients has been evaluated in several fully powered randomized controlled clinical trials. In these five trials, DTG-based regimens were noninferior or superior to a comparator INSTI-, NNRTI-, or PI-based regimen. The primary efficacy endpoint in these clinical trials was the proportion of participants with plasma HIV RNA <50 copies/mL.
DTG plus Two NRTIs versus Other INSTIs plus Two NRTIs:

- DTG-based regimens (with TAF/FTC or ABC/3TC) have been compared to BIC/TAF/FTC in two randomized controlled trials. These regimens have shown virologic efficacy that is similar to BIC/TAF/FTC (see the discussion in the BIC section above).4,5

- The SPRING-2 trial compared DTG 50 mg once daily to RAL 400 mg twice daily. Each drug was administered in combination with an investigator-selected, two-NRTI regimen (either ABC/3TC or TDF/FTC) to 822 participants. At week 96, DTG was noninferior to RAL.70

DTG/ABC/3TC versus EFV/TDF/FTC:

- The SINGLE trial compared the use of DTG 50 mg once daily plus ABC/3TC to EFV/TDF/FTC in 833 participants. At week 48, DTG was superior to EFV, primarily because the study treatment discontinuation rate was higher in the EFV arm than in the DTG arm.31 At week 144, DTG plus ABC/3TC remained superior to EFV/TDF/FTC.89

DTG plus Two NRTIs versus PI/r plus Two NRTIs:

- The FLAMINGO study, a randomized open-label clinical trial, compared DTG 50 mg once daily to DRV/r 800 mg/100 mg once daily, each administered in combination with investigator-selected ABC/3TC or TDF/FTC. At week 48, DTG was superior to DRV/r because of the higher rate of discontinuation in the DRV/r arm.90 The difference in efficacy between the DTG and DRV/r regimens was more pronounced in patients with pretreatment HIV RNA levels >100,000 copies/mL. At week 96, DTG remained superior to DRV/r.91

- The ARIA trial, an open-label, Phase 3b randomized controlled trial, compared the efficacy and safety of DTG/ABC/3TC to ATV/r plus TDF/FTC in ART-naive, nonpregnant women. At week 48, 82% of participants in the DTG group achieved HIV RNA viral loads <50 copies/mL compared with 71% in the ATV group (P = 0.005). The difference was driven by a lower rate of virologic nonresponse and fewer withdrawals due to adverse events in the DTG group.92

DTG plus Two NRTIs versus DTG plus 3TC:

- Data are emerging that support the use of two-drug therapy with DTG plus 3TC. The results of a large randomized controlled trial that compared DTG plus TDF/FTC with DTG plus 3TC are discussed in the Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used section below.

Adverse Effects:

- DTG is generally well tolerated. The most commonly reported adverse reactions of moderate-to-severe intensity were insomnia and headache.

- Case series of neuropsychiatric adverse events (sleep disturbances, depression, anxiety, suicidal ideation) associated with the initiation of DTG and RAL have been reported.93,94 Two observational cohort studies reported a higher frequency of neuropsychiatric adverse events leading to treatment discontinuation in patients receiving DTG than in patients receiving other INSTIs.95,96 However, analyses of data from large randomized controlled trials as well as a health care database demonstrated similar rates of neuropsychiatric adverse events between DTG-based regimens and other ARV regimens,97 with neuropsychiatric events rarely leading to DTG discontinuation. Another report from the World Health Organization international pharmacovigilance database reported neuropsychiatric events with all approved INSTIs,98 not just DTG. Further studies will be needed to clarify the true incidence and implications of these neuropsychiatric events. A pathophysiologic mechanism for these neuropsychiatric...
• Preliminary data from an observational surveillance study of birth outcomes among pregnant women on ART in Botswana identified NTDs in four infants born to 596 women (0.67%) who initiated a DTG-based regimen prior to pregnancy, and who were still receiving it at the time of conception. The incidence of NTDs among infants born to women who were receiving other ARV drugs at the time of conception was 0.1%. This study is ongoing, and more data from births among women who were using a DTG-based regimen around the time of conception are expected. See Table 6b for recommendations on prescribing INSTIs as part of initial therapy.

Other Factors and Considerations:

• DTG, like BIC, decreases tubular secretion of creatinine without affecting glomerular function, with increases in serum creatinine observed within the first 4 weeks of treatment (mean increase in serum creatinine was 0.11 mg/dL after 48 weeks).

• DTG has fewer drug interactions than EVG/c. See Drug-Drug Interactions for specific drug-drug interactions that require dosage adjustment.

• DTG absorption, like absorption for other INSTIs, may be reduced when the ARV is coadministered with polyvalent cations (see Drug-Drug Interactions). DTG should be taken at least 2 hours before or 6 hours after cation-containing antacids or laxatives. Alternatively, DTG and supplements containing calcium or iron can be taken simultaneously with food.

• Treatment-emergent mutations that confer DTG resistance have not been reported in patients receiving DTG as part of a three-drug regimen for initial therapy, which suggests that DTG, like BIC, has a higher barrier to resistance than EVG or RAL.

The Panel’s Recommendations:

• On the basis of clinical trial data, the Panel categorizes DTG in combination with ABC/3TC (AI), TAF/FTC (AI), or TDF/FTC (AI) as a Recommended Initial Regimen for Most People with HIV.

• A pregnancy test should be performed for those of childbearing potential prior to initiation of DTG (AIII).

• For those of childbearing potential who are using effective contraception, a DTG-based regimen can be considered after weighing the risks and benefits of DTG with the individual (BIII).

• Until more information is available, DTG should not be prescribed for individuals:
  • Who are pregnant and within 12 weeks post-conception (AII); or
  • Who are of childbearing potential and who are planning to become pregnant (AII) or who are sexually active and not using effective contraception (AIII).

Ralt gr avir (RAL)

RAL was the first INSTI approved for use in both ARV-naive and ARV-experienced patients.

Efficacy in Clinical Trials

RAL 400 mg Twice Daily plus Two NRTIs versus Comparator Drug plus Two NRTIs:

• The efficacy of RAL at a dose of 400 mg twice daily (with either TDF/FTC or ABC/3TC) as initial therapy was evaluated in two randomized, double-blind, controlled clinical trials and a third open-label, randomized trial.

• STARTMRK compared RAL 400 mg twice daily to EFV 600 mg once daily, each administered in
combination with TDF/FTC. RAL was noninferior to EFV at 48 weeks. RAL was superior to EFV at 4 and 5 years, in part because of more frequent discontinuations due to adverse events in the EFV group than in the RAL group.

- The SPRING-2 trial compared DTG 50 mg once daily to RAL 400 mg twice daily, each administered in combination with investigator-selected ABC/3TC or TDF/FTC. At week 96, DTG was noninferior to RAL.
- The SPRING-2 trial also provided nonrandomized data on the efficacy of RAL plus ABC/3TC. In this trial, 164 participants (39 participants with baseline viral loads ≥100,000 copies/mL and 125 participants with baseline viral loads <100,000 copies/mL) received RAL in combination with ABC/3TC. After 96 weeks, there was no difference in virologic response between the ABC/3TC and TDF/FTC groups when RAL was given as the third drug.
- ACTG A5257, a large randomized open-label trial, compared three NNRTI-sparing regimens that contained RAL, ATV/r, or DRV/r, each given with TDF/FTC. At week 96, all three regimens had similar virologic efficacy, but RAL was superior to both ATV/r and DRV/r for the combined endpoints of virologic efficacy and tolerability. Participants had greater increases in lipid levels in the PI/r arms than in the RAL arm, and BMD decreased to a greater extent in participants in the PI/r arms than in participants in the RAL arm.

**RAL 1,200 mg Once Daily plus TDF/FTC versus RAL 400 mg Twice Daily plus TDF/FTC:**

- In a Phase 3, randomized, double-blind, active comparator-controlled trial (the ONCEMRK trial), the efficacy of once-daily RAL 1,200 mg (formulated as two 600-mg tablets) was compared to RAL 400 mg twice daily, each administered with TDF/FTC. At 96 weeks, a similar proportion of participants in both groups achieved HIV RNA suppression (81.5% in the once-daily arm vs. 80.1% in the twice-daily arm). The responses were similar regardless of baseline HIV RNA or CD4 cell count.

**Adverse Effects:**

- RAL use has been associated with creatine kinase elevations. Myositis and rhabdomyolysis have been reported.
- Rare cases of severe skin reactions and systemic HSRs in patients who received RAL have been reported during post-marketing surveillance.
- Neuropsychiatric adverse events (e.g., insomnia, headache, depression, and suicidal ideation) have been reported in people receiving INSTIs (see the discussion under DTG).

**Other Factors and Considerations:**

- RAL can be administered as 1,200 mg (two 600-mg tablets) once daily or as 400 mg twice daily with or without food in ART-naive patients.
- Coadministration of RAL as either 400 mg twice daily or 1,200 mg once daily with aluminum-containing and/or magnesium-containing antacids is not recommended. Calcium carbonate-containing antacids may be coadministered with RAL 400 mg twice daily, but not with RAL 1,200 mg once daily. Polyvalent cation-containing supplements may also reduce absorption of RAL. See Table 19d for dosing recommendations.
- RAL has a lower barrier to resistance than RTV-boosted PIs, BIC, and DTG.

**The Panel’s Recommendations:**

- On the basis of these clinical trial data, the Panel considers RAL given as 1,200 mg (two 600-mg tablets)
once daily or as 400 mg twice daily plus TDF/FTC (BI) or TAF/FTC (BII) as a Recommended Initial Regimen for Most People with HIV.

- Because fewer patients have received RAL plus ABC/3TC in clinical trials or practice and there has not been a randomized trial comparing ABC/3TC plus RAL to TDF/FTC plus RAL, the Panel categorizes RAL plus ABC/3TC as a Recommended Initial Regimen in Certain Clinical Situations (BII).

**Integrase Strand Transfer Inhibitors Recommended as Part of an Initial Regimen in Certain Clinical Situations**

**Elvitegravir (EVG)**

EVG is available as a component of two STRs: EVG/c/TDF/FTC and EVG/c/TAF/FTC. COBI is a specific, potent CYP3A inhibitor that has no activity against HIV. It acts as a PK enhancer of EVG, which allows for once-daily dosing of the combination but increases the likelihood of significant drug interactions.

**Efficacy in Clinical Trials:**

- The efficacy of EVG/c/TDF/FTC in ART-naive participants has been evaluated in two randomized, double-blind active-controlled trials.
  - At 144 weeks, EVG/c/TDF/FTC was noninferior to fixed-dose EFV/TDF/FTC.\(^{103}\)
  - EVG/c/TDF/FTC was also found to be noninferior to ATV/r plus TDF/FTC.\(^ {104}\)
  - In a randomized, blinded trial performed in women with HIV, EVG/c/TDF/FTC had superior efficacy when compared to ATV/r plus TDF/FTC, in part because of a lower rate of treatment discontinuation.\(^ {15}\)
- The efficacy of EVG/c/TAF/FTC in ART-naive participants has been evaluated in two randomized, double-blind controlled trials in adults with eGFR ≥50 mL/min.\(^ {32,35}\)
  - At 48 and 96 weeks, TAF was noninferior to TDF when both drugs were combined with EVG/c/FTC; at 144 weeks, EVG/c/TAF/FTC was superior to EVG/c/TDF/FTC.\(^ {33}\)

**Adverse Effects:**

- The most common adverse events reported with EVG/c/TDF/FTC were diarrhea, nausea, upper respiratory infection, and headache.\(^ {103,104}\)
- The most common adverse events reported with EVG/c/TAF/FTC were nausea, diarrhea, headache, and fatigue.\(^ {105}\)
- Neuropsychiatric adverse events have been reported in people receiving INSTIs (see the discussion under DTG).

**Other Factors and Considerations:**

- EVG is metabolized primarily by CYP3A enzymes; as a result, CYP3A inducers or inhibitors may alter EVG concentrations.
- Because COBI inhibits CYP3A, it interacts with a number of medications that are metabolized by this enzyme (see Drug-Drug Interactions).\(^ {106}\)
- Administering EVG simultaneously with polyvalent cation-containing antacids or supplements lowers EVG plasma concentrations (see Drug-Drug Interactions). Separate EVG/c/TDF/FTC or EVG/c/TAF/FTC and polyvalent antacid administration by at least 2 hours; administer polyvalent cation-containing supplements at least 2 hours before or 6 hours after EVG dosing.
- COBI inhibits active tubular secretion of creatinine, resulting in increases in serum creatinine and a reduction in estimated CrCl without reducing glomerular function.\textsuperscript{107} Patients with a confirmed increase in serum creatinine >0.4 mg/dL from baseline while taking EVG/c/TDF/FTC should be closely monitored and evaluated for evidence of TDF-related proximal renal tubulopathy.\textsuperscript{83}

- **EVG/c/TDF/FTC is not recommended** for patients with pretreatment estimated CrCl <70 mL/min.\textsuperscript{83}

- **EVG/c/TAF/FTC is not recommended** for patients with pretreatment estimated CrCl <30 mL/min.

- At the time of virologic failure, INSTI-associated mutations were detected in some EVG/c/TDF/FTC-treated patients whose therapy failed.\textsuperscript{103,104} These mutations conferred cross-resistance to RAL, with most patients retaining susceptibility to DTG.

The Panel’s Recommendation:

- On the basis of the above considerations, the Panel classifies EVG/c/TAF/FTC and EVG/c/TDF/FTC as **Recommended Initial Regimens in Certain Clinical Situations (B1)**. EVG/c/TAF/FTC should only be used in people with estimated CrCl ≥30 mL/min; EVG/c/TDF/FTC should only be used in people with estimated CrCl ≥70 mL/min.

### Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens

**Table 8c. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors that are Recommended for Antiretroviral Therapy-Naive Patients**

<table>
<thead>
<tr>
<th></th>
<th>DOR</th>
<th>EFV</th>
<th>RPV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing Frequency</strong></td>
<td>Once daily</td>
<td>Once daily</td>
<td>Once daily</td>
</tr>
<tr>
<td><strong>Food Requirement</strong></td>
<td>With or without food</td>
<td>On an empty stomach</td>
<td>With a meal</td>
</tr>
<tr>
<td><strong>STR Available for ART-Naive Patients</strong></td>
<td>• DOR/TDF/3TC</td>
<td>• EFV 600 mg/TDF/FTC</td>
<td>• RPV/TAF/FTC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EFV 600 mg/TDF/3TC</td>
<td>• RPV/TDF/FTC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EFV 400 mg/TDF/3TC</td>
<td></td>
</tr>
<tr>
<td><strong>Available as a Single-Drug Tablet</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Generally well tolerated</td>
<td>• CNS side effects, including dizziness, abnormal dreams, headache, depression, suicidality, somnolence, and insomnia</td>
<td>• Depression, headache</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Skin rash</td>
<td></td>
</tr>
<tr>
<td><strong>CYP3A4 Drug-Drug Interactions</strong></td>
<td>CYP3A4 substrate</td>
<td>CYP3A4 substrate, mixed inducer/inhibitor</td>
<td>CYP3A4 substrate</td>
</tr>
<tr>
<td><strong>Other Significant Drug Interactions</strong></td>
<td>None</td>
<td>CYP2B6 and 2C19 inducer</td>
<td>RPV oral absorption is reduced with increased gastric pH. Use of RPV with PPIs is not recommended; see <strong>Drug-Drug Interactions</strong> for dosing recommendations when RPV is coadministered with H2 blocker or antacids.</td>
</tr>
</tbody>
</table>

**Key to Acronyms:** 3TC = lamivudine; CNS = central nervous system; CYP = cytochrome P; DOR = doravirine; EFV = efavirenz; FTC = emtricitabine; H2 = histamine 2; PPI = proton pump inhibitor; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
Summary

Five NNRTIs (delavirdine [DLV], DOR, EFV, etravirine [ETR], nevirapine [NVP], and RPV) are currently approved by the FDA for the treatment of HIV when used in combination with other ARV drugs.

NNRTI-based regimens have demonstrated virologic potency and durability. The major disadvantages of currently available NNRTIs (especially EFV and RPV) are the prevalence of NNRTI-resistant viral strains in ART-naive patients and the drugs’ low barrier for the development of resistance. Resistance testing should be performed to guide therapy selection for ART-naive patients (see Drug-Resistance Testing). High-level resistance to all NNRTIs (except ETR or DOR) may occur with a single mutation. In RPV-treated patients, the presence of RPV resistance mutations at virologic failure may confer cross-resistance to other NNRTIs, including ETR. DOR, EFV-, and RPV-based regimens are now categorized as Recommended Initial Regimens in Certain Clinical Situations for ART-naive patients.

Doravirine (DOR)

Efficacy in Clinical Trials

The efficacy of DOR-based therapy for treatment of HIV in ART-naive individuals was demonstrated in two randomized, double-blind, placebo-controlled trials.

DOR-Based Regimen versus EFV-Based Regimen:

- In DRIVE-AHEAD, 734 participants received either DOR/TDF/3TC or EFV/TDF/FTC, both as STRs.
  - At 48 weeks, DOR/TDF/3TC was found to be noninferior to EFV/TDF/FTC, with 84.3% of participants who received DOR/TDF/3TC and 80.8% of those who received EFV/TDF/FTC achieving HIV RNA <50 copies/mL. Virologic responses overall were lower in participants with pre-ART HIV RNA >100,000 copies/mL, but there was no difference between the DOR and EFV groups.
  - A greater proportion of participants in the EFV arm discontinued their assigned ART due to adverse events than in the DOR arm (6.3% vs. 2.7%). Neuropsychiatric side effects were more common in the EFV arm.
  - Genotype resistance results were reported for 13 participants with virologic failure in the DOR arm and 10 participants in the EFV arm. For the DOR arm, seven out of 13 participants had NNRTI resistance and five out of 13 had NRTI resistance; for EFV, nine out of 10 participants had NNRTI resistance and five out of 10 had NRTI resistance.
  - The DOR group had no change in LDL cholesterol and non-HDL cholesterol among participants, whereas both LDL and non-HDL cholesterol increased with EFV use.
  - At week 96, 77.5% and 73.6% of participants in the DOR arm and the EFV arm had maintained HIV RNA <50 copies/mL, respectively.

DOR-Based Regimen versus DRV/r-Based Regimen:

- In DRIVE-FORWARD, 769 participants received DOR or DRV/r once daily along with two investigator-selected NRTIs, either ABC/3TC or TDF/FTC.
  - At 48 weeks, DOR was found to be noninferior to DRV/r when these drugs were administered with two NRTIs. Eighty-four percent of study participants receiving DOR achieved HIV RNA <50 copies/mL at 48 weeks, compared to 80% of participants receiving DRV/r.
  - Participants who received DOR plus ABC/3TC (n = 48) and those who received DOR plus TDF/FTC (n = 316) had similar virologic responses.
  - At week 96, DOR was superior to DRV/r in terms of virologic suppression, there was a higher rate of discontinuation in the DRV/r group.
• Genotype resistance results were reported for seven and eight participants with virologic failure in the DOR and DRV/r arms, respectively. No drug resistance mutations were detected in either group.

• Treatment-related diarrhea was more frequently reported in the DRV/r arm, and greater increases in fasting LDL cholesterol and triglycerides were seen in the participants who received DRV/r than in those who received DOR.

Other Factors and Considerations:

• DOR is available as a single-drug, 100-mg tablet and as part of an STR that contains DOR/TDF/FTC 100 mg/300 mg/300 mg and is dosed once daily, with or without food.

• DOR is primarily metabolized by the CYP3A4 enzyme and should not be coadministered with strong CYP3A4 inducers. DOR concentration may increase in the presence of a CYP3A4 inhibitor (see Table 19b).

• DOR is not a CYP3A4 inducer or inhibitor, so it is not expected to affect the concentrations of concomitant CYP3A4 substrates.

• Treatment-emergent resistance mutations to DOR may confer cross-resistance to certain other NNRTIs. Most isolates with DOR mutations remain susceptible to ETR.

• DOR-based regimens have not been directly compared to INSTI-based regimens in clinical trials.

• There are currently no data on the safety of DOR use during pregnancy.

The Panel’s Recommendations:

• On the basis of the clinical trial data discussed above, the Panel classifies DOR/TDF/3TC (BI) and DOR plus two NRTIs (BI for TDF/FTC and BIII for TAF/FTC) as Recommended Initial Regimens in Certain Clinical Situations.

• Because the number of participants who received DOR plus ABC/3TC is much lower than the number who received TDF/FTC plus DOR, the Panel considers ABC/3TC plus DOR to be an option for initial therapy, but the Panel has less confidence in this regimen than in the other DOR-containing regimens listed above (CI).

Efavirenz (EFV)

Efficacy in Clinical Trials:

• Large randomized controlled trials and cohort studies in ART-naive patients have demonstrated potent and durable viral suppression in patients treated with EFV plus two NRTIs. In clinical trials, EFV-based regimens have demonstrated superiority or noninferiority to several comparator regimens in ART-naive patients.

• In ACTG 5202, EFV was comparable to ATV/r when each was given with either TDF/FTC or ABC/3TC.

• In the ECHO and THRIVE studies, EFV was noninferior to RPV, with less virologic failure. However, EFV caused more discontinuations due to adverse events. The virologic advantage of EFV was most notable in participants with pre-ART viral loads >100,000 copies/mL, and NRTI and NNRTI resistance occurred more frequently in patients who experienced failure on a regimen that included RPV.

• In the GS 102 study, EFV/TDF/FTC was noninferior to EVG/c/TDF/FTC.

• The DRIVE-AHEAD study compared EFV/TDF/FTC to DOR/TDF/3TC in ART-naive patients. At 48
weeks, DOR/TDF/3TC was found to be noninferior to EFV/TDF/FTC, as discussed in the DOR section. Neuropsychiatric side effects were more common in the EFV arm.

Some regimens have demonstrated superiority to EFV, based primarily on fewer discontinuations because of adverse events:

• In the SINGLE trial, a DTG-based regimen was superior to EFV at the primary endpoint of viral suppression at week 48.31

• In the STARTMRK trial, RAL was noninferior to EFV at 48 weeks,66 but RAL was superior to EFV at 4 and 5 years,69,99 in part because of more frequent discontinuations due to adverse events in the EFV group than in the RAL group.

• In the open-label STaR trial, participants with baseline viral loads ≤100,000 copies/mL had higher rates of treatment success on RPV than on EFV.118

ENCORE 1 (a multinational, randomized, placebo-controlled trial) compared two once-daily doses of EFV (combined with TDF/FTC): EFV 600 mg (standard dose) versus EFV 400 mg (reduced dose). At 96 weeks, EFV 400 mg was noninferior to EFV 600 mg for rate of viral suppression.119 While the frequency of overall adverse events was not different between groups, EFV-related adverse events occurred less frequently in the EFV 400 mg group than in the EFV 600 mg group. Although there were fewer self-reported CNS events in the 400 mg group, the groups had similar rates of psychiatric events. The 400-mg dose of EFV is now approved in the United States for initial treatment of HIV infection and is coformulated with TDF and 3TC in an FDC tablet. However, long-term experience and clinical efficacy data regarding its use during pregnancy and in patients with TB/HIV coinfection are lacking.

Adverse Effects:

• EFV can cause CNS side effects (e.g., abnormal dreams, dizziness, headache, and depression) that resolve over a period of days to weeks in most patients. However, subtler, long-term neuropsychiatric effects can occur.

• EFV use has also been associated with suicidality; however, various large studies have provided different results. An analysis of four ACTG comparative trials showed a higher rate of suicidality (i.e., reported suicidal ideation or attempted or completed suicide) among EFV-treated patients than among patients taking comparator regimens (LPV/r, ATV, ATV/r, or ABC-based regimens).120 Similarly, a subgroup analysis of the START trial revealed higher risk of suicidal or self-injurious behavior among participants in the immediate ART group who took EFV than among ART-naive controls; the risk increased for those with previous psychiatric diagnoses.121 This association, however, was not found in analyses of three large observational cohorts,122,123 or in a retrospective cohort study that used U.S. administrative pharmacy claims data.124 A prospective observational cohort study among people with HIV in Uganda revealed no evidence that EFV carried an increased risk of suicidal ideation or depression compared to NVP.125

• EFV may cause elevation in LDL cholesterol and triglycerides.

• QTc interval prolongation has been observed with EFV use.126,127 Consider an alternative therapy to EFV in patients taking medications known to increase the risk of Torsades de Pointes, or in patients at higher risk of Torsades de Pointes.

Other Factors and Considerations:

• EFV is formulated both as a single-drug, 600-mg tablet and in an FDC tablet of EFV/TDF/FTC that allows for once-daily dosing.
• EFV is also available as a generic single-drug, 600-mg tablet and as a generic once-daily STR tablet that uses 3TC, TDF, and either 600 mg or 400 mg of EFV; the lower-dose EFV/TDF/3TC tablet is approved for treating adults and children who weigh ≥35 kg.128,129

• EFV is a substrate of CYP3A4 and an inducer of CYP3A4 and 2D6; therefore, it may potentially interact with other drugs that use the same pathways (see Tables 19b, 20a, and 20b).

• EFV has been associated with CNS birth defects in nonhuman primates, and cases of NTDs have been reported after first-trimester exposure in humans.130 A link between EFV and birth defects in humans has not been supported in meta-analyses (see the Perinatal Guidelines).131

Screening for depression and suicidality is recommended for people with HIV who are taking a regimen that includes EFV.

The Panel’s Recommendations:

• Given the availability of regimens with fewer treatment-limiting adverse events and also with noninferior or superior efficacy, the Panel classifies EFV/TDF/FTC or EFV/TDF/3TC (BI) or EFV plus TAF/FTC (BII) as Recommended Initial Regimens in Certain Clinical Situations.

• Randomized clinical trial data have demonstrated the efficacy of lower-dose (400 mg) EFV,119 but this dose has not been studied in a U.S. population, in pregnant women, or in patients with TB/HIV coinfection. The Panel therefore classifies the use of reduced-dose EFV as a Recommended Initial Regimen in Certain Clinical Situations (CI).

Rilpivirine (RPV)

RPV is an NNRTI that is approved for use in combination with NRTIs for ART-naive patients with pretreatment viral loads <100,000 copies/mL.

Efficacy in Clinical Trials:

• Two Phase 3 randomized, double-blind clinical trials—ECHO and THRIVE—compared RPV and EFV, each combined with two NRTIs.117 At 96 weeks, the following findings were reported:
  • RPV was noninferior to EFV overall.
  • Among participants with pre-ART viral loads >100,000 copies/mL, more RPV-treated participants than EFV-treated participants experienced virologic failure. Moreover, in this subgroup of participants with virologic failure, NNRTI and NRTI resistance was more frequently identified in those treated with RPV.
  • Among the RPV-treated participants, the rate of virologic failure was greater in those with pretreatment CD4 cell counts <200 cells/mm³ than in those with CD4 cell counts ≥200 cells/mm³.
  • STaR, a Phase 3b, open-label study, compared the FDC of RPV/TDF/FTC and EFV/TDF/FTC in 786 treatment-naive patients. The results at 96 weeks132 were similar to the findings reported at 48 weeks.118
    • RPV was noninferior to EFV overall.
    • RPV was superior to EFV in patients with pre-ART viral loads ≤100,000 copies/mL and noninferior in those with pre-ART viral loads >100,000 copies/mL. Among patients with pre-ART viral loads >500,000 copies/mL, virologic failure was more common in RPV-treated patients than in EFV-treated patients.
    • There were more participants with emergent resistance in the RPV/FTC/TDF arm than in the EFV/FTC/TDF arm (4% vs. 1%, respectively).
  • The FDC tablet of RPV/TAF/FTC was approved by the FDA based on results from a bioequivalence
study. In this study, participants taking the coformulated drug had plasma concentrations of RPV, FTC, and TAF 25 mg that were similar to concentrations seen in participants who received RPV as the single-drug tablet and TAF/FTC when given as part of the FDC of EVG/c/TAF 10 mg/FTC.\(^6\)

**Adverse Effects:**

- RPV is generally well tolerated. In the ECHO, THRIVE, and STaR trials, fewer instances of CNS adverse events (e.g., abnormal dreams, dizziness, psychiatric side effects), skin rash, and dyslipidemia were reported in the RPV arms than in the EFV arms, and fewer patients in the RPV arms discontinued therapy due to adverse events. However, up to 9% of clinical trial participants experienced depressive disorders, including approximately 1% of participants who had suicidal thoughts or who attempted suicide. Patients with severe depressive symptoms should be evaluated to assess whether symptoms may be due to RPV and if the risks of continuing the same regimen outweigh the benefits.

**Other Factors and Considerations:**

- RPV is formulated both as a single-drug tablet and in STRs with TAF/FTC and with TDF/FTC. Among available STRs, RPV/TAF/FTC is the smallest tablet.
- RPV/TAF/FTC and RPV/TDF/FTC are given once daily and must be administered with a meal (containing at least 390 kcal).
- RPV is also coformulated as a once-daily FDC tablet with DTG that is used as continuation therapy for persons with HIV who have achieved viral suppression.\(^3\) However, this combination has not been studied in ART-naive individuals, and it is not recommended for initial therapy (see Optimizing Antiretroviral Therapy in the Setting of Viral Suppression).
- The oral drug absorption of RPV can be significantly reduced in the presence of acid-lowering agents. RPV is contraindicated in patients who are receiving proton pump inhibitors (PPIs), and should be used with caution in those receiving H2 antagonists or antacids (see Drug-Drug Interactions for dosing recommendations).
- RPV is primarily metabolized in the liver by the CYP3A enzyme; its plasma concentration may be affected in the presence of CYP3A inhibitors or inducers (see Drug-Drug Interactions).
- At doses above the approved dose of 25 mg, RPV may cause QTc interval prolongation. RPV should be used with caution when coadministered with a drug known to increase the risk of Torsades de Pointes.

**The Panel’s Recommendations:**

- Given the availability of other effective regimens that do not have virologic and immunologic prerequisites to initiate treatment, the Panel recommends RPV/TDF/FTC and RPV/TAF/FTC as Recommended Initial Regimens in Certain Clinical Situations.
- Use of RPV with TAF/FTC (BII) or TDF/FTC (BI) should be limited to ART-naive patients with pretreatment viral loads <100,000 copies/mL and CD4 cell counts >200 cells/mm\(^3\).
- Data on RPV plus ABC/3TC are insufficient to consider recommending this regimen.
Protease Inhibitor-Based Regimens

Table 8d. Characteristics of Protease Inhibitor Options that are Recommended for Antiretroviral Therapy-Naive Patients

<table>
<thead>
<tr>
<th></th>
<th>ATV</th>
<th>DRV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing Frequency</strong></td>
<td>Once daily</td>
<td>• Once daily for PI-naive patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Twice daily for PI-experienced patients with certain PI mutations</td>
</tr>
<tr>
<td><strong>PK Boosting</strong></td>
<td>PK-boosting with RTV or COBI is generally recommended. Unboosted ATV is also FDA-approved for ART-naive patients.</td>
<td>DRV should only be used with a PK booster (i.e., RTV or COBI).</td>
</tr>
<tr>
<td><strong>Fixed-Dose Formulation</strong></td>
<td>• ATV/c</td>
<td>• DRV/c</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DRV/c/TAF/FTC</td>
</tr>
<tr>
<td><strong>Available as a Single-Drug Tablet</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>• Jaundice</td>
<td>• Skin rash</td>
</tr>
<tr>
<td></td>
<td>• Indirect hyperbilirubinemia</td>
<td>• Increase in serum transaminases</td>
</tr>
<tr>
<td></td>
<td>• Cholelithiasis</td>
<td>• Hyperlipidemia</td>
</tr>
<tr>
<td></td>
<td>• Nephrolithiasis</td>
<td>• A higher cardiovascular risk was reported in participants taking DRV-based regimens than in those taking ATV-based regimens in an observational cohort study.</td>
</tr>
<tr>
<td><strong>CYP3A4 Drug-Drug Interactions</strong></td>
<td>CYP3A4 substrate, inhibitor</td>
<td>CYP3A4 substrate, inhibitor</td>
</tr>
<tr>
<td><strong>Other Significant Drug Interactions</strong></td>
<td>ATV absorption is reduced when ATV is given with acid-lowering therapies. See Table 19a for ATV dosing recommendations when the drug is coadministered with acid-lowering agents.</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Key to Acronyms: ART = antiretroviral therapy; ATV = atazanavir; ATV/c = atazanavir/cobicistat; COBI = cobicistat; CYP = cytochrome P; DRV = darunavir; DRV/c = darunavir/cobicistat; FDA = Food and Drug Administration; FTC = emtricitabine; PI = protease inhibitor; PK = pharmacokinetic; RTV = ritonavir; TAF = tenofovir alafenamide

**Summary**

FDA-approved PIs include ATV, ATV/c, DRV, DRV/c, fosamprenavir (FPV), indinavir (IDV), LPV/r, nelfinavir (NFV), RTV, saquinavir (SQV), and tipranavir (TPV). PI-based regimens with PK enhancement (also called boosting) have demonstrated virologic potency, durability in treatment-naive patients, and a high barrier to resistance. Because transmitted PI resistance is uncommon, PI-based regimens are generally recommended if early ART initiation is necessary, before resistance test results are available. Few or no PI mutations are detected when a patient’s first PI-based regimen fails, which is not the case with NNRTI-based regimens and some INSTI-based regimens.134,135 For this reason, PI-based regimens may be useful for patients at risk for intermittent therapy due to poor adherence. All PIs (boosted by either RTV or COBI) inhibit the CYP3A4 isoenzyme, which may lead to significant drug-drug interactions (see Drug-Drug Interactions). Each PI has specific characteristics related to its virologic potency, adverse effects profile, and PK properties. The characteristics of recommended PIs are listed in Table 9 and Appendix B, Table 3.

PIs that are recommended for use in ART-naive patients should have proven virologic efficacy, once-daily dosing, a lower pill count than older PI-based regimens, and good tolerability. On the basis of these criteria, the Panel considers once-daily DRV/r, DRV/c, ATV/c, or ATV/r together with two NRTIs as PI-based regimen options in the category of Recommended Initial Regimens in Certain Clinical Situations. DRV/c/TAF/FTC is now available as an STR. In a large, randomized controlled trial comparing DRV/r, ATV/r,
and RAL, each administered in combination with TDF/FTC, all three regimens achieved similar virologic suppression rates; however, the proportion of patients who discontinued their assigned treatment because of adverse effects, mainly hyperbilirubinemia, was greater in the ATV/r arm than in the other two arms.\textsuperscript{11}

Several metabolic abnormalities, including dyslipidemia and insulin resistance, have been associated with PI use. The currently available PIs differ in their propensity to cause these metabolic complications, which also depends on the dose of RTV used as a PK-enhancing agent. Large observational cohort studies found an association between some PIs (i.e., DRV/r, FPV, IDV, and LPV/r) and an increased risk of cardiovascular events; this risk was not seen with ATV.\textsuperscript{18-20,23} Another observational cohort study of predominantly male participants found a lower rate of cardiovascular events in those receiving ATV-containing regimens compared to those receiving other regimens.\textsuperscript{22} Further study is needed.

Compared to other PIs, LPV/r, FPV/r, unboosted ATV, and SQV/r have disadvantages such as greater pill burden, lower efficacy, or increased toxicity, and thus are no longer included as options for initial therapy.

**Darunavir/Ritonavir (DRV/r)**

**Efficacy in Clinical Trials:**

- The ARTEMIS study compared DRV/r (800 mg/100 mg once daily) with LPV/r (800 mg/200 mg once daily or 400 mg/100 mg twice daily), both administered in combination with TDF/FTC, in a randomized, open-label, noninferiority trial. DRV/r was noninferior to LPV/r at week 48,\textsuperscript{64} and superior at week 192.\textsuperscript{136} Among participants with baseline HIV RNA levels >100,000 copies/mL, virologic response rates were lower in the LPV/r arm than in the DRV/r arm.

- The FLAMINGO study compared DRV/r with DTG, each administered in combination with two NRTIs, in 488 ART-naive participants. The rate of virologic suppression at week 96 was significantly greater among those who received DTG than in those who received DRV/r. The excess failure observed in the DRV/r group was primarily related to a higher rate of virologic failure among those with a viral loads >100,000 copies/mL and secondarily due to more drug discontinuations in the DRV/r group.\textsuperscript{14}

- ACTG A5257, a large randomized open-label trial, compared ATV/r with DRV/r or RAL, each given with TDF/FTC. The trial showed similar virologic efficacy for DRV/r, ATV/r, and RAL, but more participants in the ATV/r group discontinued randomized treatment because of adverse events.\textsuperscript{11}

- The DRIVE-FORWARD study compared DRV/r to DOR, both administered with two investigator-selected NRTIs, in ARI-naive participants. At 48 weeks, DOR was found to be noninferior to DRV/r, with 80% of participants who received DOR achieving HIV RNA levels <50 copies/mL compared with 84% of participants who received DRV/r.

**Adverse Effects:**

- Patients taking DRV/r may develop a skin rash, which is usually mild-to-moderate in severity and self-limited. Treatment discontinuation is necessary on rare occasions when severe rash with fever or elevated transaminases occur.

- ACTG A5257 showed similar lipid changes in participants in the ATV/r and DRV/r arms. BMD decreased to a greater extent in participants in the ATV/r and DRV/r arms than in participants in the RAL arm.\textsuperscript{11} The likelihood of developing metabolic syndrome was equivalent between the three arms, although a larger increase in waist circumference was observed at 96 weeks in participants assigned to the RAL arm than in those assigned to the DRV/r arm (\(P \leq 0.02\)).\textsuperscript{137}

- An observational cohort study suggested that DRV/r is associated with increased rates of cardiovascular disease.\textsuperscript{23}
Other Factors and Considerations:

- **DRV/r** is administered once daily with food in treatment-naive patients.
- **DRV** has a sulfonamide moiety and should be used with caution in patients with severe sulfonamide allergies. In clinical trials, the incidence and severity of rash were similar in participants who did or did not have a history of sulfonamide allergy. Most patients with sulfonamide allergy are able to tolerate DRV.
- **DRV/r** is a potent CYP3A4 inhibitor, and this may lead to significant interactions with other medications metabolized through this same pathway (see Drug-Drug Interactions).

The Panel’s Recommendations:

- On the basis of efficacy and safety data from clinical trials and clinical experience, the Panel classifies DRV/r with TDF/FTC (AI), with TAF/FTC (AII), or with ABC/3TC (BII) as Recommended Initial Regimens in Certain Clinical Situations.

**Darunavir/Cobicistat (DRV/c)**

A combination of DRV 800 mg with COBI 150 mg is bioequivalent to DRV 800 mg with RTV 100 mg in healthy volunteers, based on the maximum concentration and area under the concentration time curve for DRV. Because the minimum concentration (C_{min}) of DRV combined with COBI was 31% lower than that of DRV combined with RTV, bioequivalence for the C_{min} was not achieved.

**Efficacy in Clinical Trials:**

- The AMBER trial enrolled 725 ART-naive participants in a Phase 3 randomized controlled trial that compared the STR DRV/c/TAF/FTC and DRV/c plus TDF/FTC. At 48 weeks, similar virologic suppression rates among participants were achieved in both arms of the study (91% and 88%, respectively). No treatment-emergent mutations associated with DRV or TAF/TDF resistance were observed in either group. In the DRV plus TAF/FTC arm, fewer participants developed proteinuria. Changes in BMD were also less pronounced among these participants.

- In a single-arm trial in which most of the patients were treatment-naive (94%), the coformulated DRV/c 800 mg/150 mg tablet was evaluated in combination with two investigator-selected NRTIs (99% of participants were given TDF/FTC). At week 48, 83% of treatment-naive participants achieved HIV RNA <50 copies/mL; 5% of participants discontinued treatment because of adverse events.

**Adverse Effects:**

- The most common drug-related adverse events were diarrhea, nausea, fatigue, flatulence, rash, and headache.

**Other Factors:**

- DRV/c 800 mg/150 mg is available as a coformulated boosted PI or as an STR with TAF/FTC 10 mg/200 mg.

The Panel’s Recommendations:

- The Panel recommends DRV/c plus TAF/FTC or TDF/FTC (AI) and DRV/c plus ABC/3TC (BII) as Recommended Initial Regimens in Certain Clinical Situations.

- DRV/c plus TDF/FTC **is not recommended** for patients with CrCl <70 mL/min, whereas DRV/c plus TAF/FTC **is not recommended** for patients with CrCl <30 mL/min.

**Atazanavir/Ritonavir (ATV/r) or Atazanavir/Cobicistat (ATV/c)**

**Efficacy in Clinical Trials:**

- **ATV/r plus Two NRTIs versus LPV/r plus Two NRTIs**
The CASTLE study compared once-daily ATV/r (300 mg/100 mg) with twice-daily LPV/r (400 mg/100 mg), each administered in combination with TDF/FTC. In this open-label, noninferiority study, the two regimens showed similar virologic and CD4 responses at 96 weeks.\textsuperscript{141}

**ATV/r plus Two NRTIs versus EFV plus Two NRTIs**

- The ACTG A5202 study compared open-label ATV/r and EFV, each given in combination with placebo-controlled TDF/FTC or ABC/3TC. Efficacy was similar in the ATV/r and EFV groups.\textsuperscript{116} In a separate analysis, women assigned to receive ATV/r were found to have a higher risk of virologic failure than women assigned to receive EFV or men assigned to receive ATV/r.\textsuperscript{142}

**ATV/r plus Two NRTIs versus INSTI plus Two NRTIs**

- In a study that compared ATV/r plus TDF/FTC to EVG/c/TDF/FTC, virologic suppression rates through 144 weeks were similar among participants in the two groups.\textsuperscript{104} A Phase 3 clinical trial of 575 women evaluated EVG/c plus FTC/TDF versus ATV/r plus FTC/TDF.\textsuperscript{15} At week 48, the virologic suppression rate in the EVG/c arm was superior to that in the ATV/r arm. Nineteen women in the PI arm discontinued therapy because of adverse events, compared to five women in the INSTI arm.

- In a Phase 3 trial, 499 ART-naive women were randomized to receive either ATV/r plus TDF/FTC or DTG/ABC/3TC. At 48 weeks, DTG was found to have a rate of virologic suppression (<50 copies/mL) that was noninferior to the rate seen in the ATV/r arm, and fewer drug-related adverse events occurred in the DTG arm.\textsuperscript{92}

**ATV/r plus Two NRTIs versus DRV/r plus Two NRTIs versus RAL plus Two NRTIs**

- In ACTG A5257, a significantly higher proportion of patients in the ATV/r arm discontinued randomized treatment because of adverse events, mostly for elevated indirect bilirubin/jaundice or gastrointestinal toxicities. Lipid changes in participants in the ATV/r and DRV/r arms were similar. BMD decreased to a greater extent in participants in the ATV/r and DRV/r arms than in participants in the RAL arm.\textsuperscript{11}

**ATV/c versus ATV/r plus Two NRTIs**

- In the Gilead Study 114, all patients received TDF/FTC and ATV and were randomized to receive either RTV or COBI as PK enhancers. Both RTV and COBI were given as a separate tablet with matching placebos.\textsuperscript{143} Through 144 weeks, the percentage of patients who achieved virologic suppression was similar in both study arms. The percentage of adverse events that caused patients to discontinue treatment and changes in serum creatinine and indirect bilirubin levels were comparable.\textsuperscript{144}

**Adverse Effects:**

- The main adverse effect associated with ATV/c or ATV/r is reversible indirect hyperbilirubinemia, with or without jaundice or scleral icterus, but without concomitant hepatic transaminase elevations. The risk for treatment-limiting indirect hyperbilirubinemia is greatest for patients who carry two UGT1A1 decreased-function alleles.\textsuperscript{145}

- Nephrolithiasis,\textsuperscript{146-148} nephrotoxicity,\textsuperscript{21} and cholelithiasis\textsuperscript{149} have also been reported in patients who received ATV.

- Both ATV/c and ATV/r can cause gastrointestinal side effects, including diarrhea.

**Other Factors and Considerations:**

- ATV/c and ATV/r are dosed once daily and with food.

- ATV requires acidic gastric pH for dissolution. As a result, concomitant use of drugs that raise gastric pH (e.g., antacids, H2 antagonists, and particularly PPIs) may impair absorption of ATV. Table 19a provides
recommendations for use of ATV/c or ATV/r with these agents.

• ATV/c and ATV/r are potent CYP3A4 inhibitors and may have significant interactions with other medications that are metabolized through this same pathway (see Drug-Drug Interactions).

• Large observational cohort studies found an association between some PIs (DRV/r, FPV, IDV, and LPV/r) and an increased risk of cardiovascular events; this risk was not seen with ATV. Another study of an observational cohort of predominantly male participants found a lower rate of cardiovascular events in participants receiving ATV-containing regimens compared with participants receiving other regimens. Further study is needed.

The Panel’s Recommendations:

• On the basis of clinical trial safety and efficacy data, the Panel classifies ATV/r and ATV/c plus TAF/FTC (BI) or TDF/FTC (BII) as Recommended Initial Regimens in Certain Clinical Situations.

• ATV/c or ATV/r plus ABC/3TC is no longer included in the list of Recommended Initial Regimens in Certain Clinical Situations, because it has disadvantages when compared with other regimens in this category. In a randomized trial, when combined with ATV/r, ABC/3TC was less potent than TDF/FTC in people with HIV RNA >100,000 copies/mL.

• ATV/c plus TDF/FTC is not recommended for patients with CrCl <70 mL/min, whereas ATV/c plus TAF/FTC is not recommended for patients with CrCl <30 mL/min.

Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal

All currently recommended ARV regimens consist of two NRTIs plus a third active drug. This strategy, however, may not be possible or optimal in all patients. In some situations, it may be necessary to avoid ABC, TAF, and TDF, such as in patients who are HLA-B*5701 positive or at high risk of cardiovascular disease and with significant renal impairment. To address these concerns, several clinical studies have evaluated strategies using initial regimens that avoid the use of two NRTIs or the NRTI drug class altogether. Clinicians should refer to HBV/HIV Coinfection for guidance on treatment of patients with HBV infection when TAF or TDF cannot be used as part of the ARV regimen.

Strategies Supported by Evidence from Clinical Trials

Dolutegravir plus Lamivudine (DTG plus 3TC)

• In the GEMINI-1 and -2 trials, a total of 1,433 ART-naive participants with baseline HIV RNA <500,000 copies/mL were randomized to receive DTG plus 3TC or DTG plus TDF/FTC. At week 48, DTG plus 3TC was noninferior to DTG plus TDF/FTC with respect to the proportion of participants with viral loads <50 copies/mL (91% and 93%, respectively). Virologic nonresponse was uncommon, occurring in 3% of participants who received DTG plus 3TC and 2% of participants who received DTG plus TDF/FTC. No instances of treatment-emergent NRTI or INSTI resistance occurred in either treatment group. Longer term follow up is ongoing.

• The PADDLE trial was a small, single-arm study of DTG plus 3TC in 20 ART-naive adults with baseline HIV RNA <100,000 copies/mL. At 48 weeks, 18 out of 20 subjects (90%) achieved HIV RNA <50 copies/mL. Fifteen of these 18 participants completed 96 weeks of treatment and maintained HIV RNA <50 copies/mL.

• The ACTG A5353 trial evaluated this same regimen in a single-arm trial that included ART-naive participants with a baseline HIV RNA of up to 500,000 copies/mL and no genotypic NRTI, INSTI, or PI resistance. The trial enrolled 120 participants; 37 participants (30.8%) had a baseline HIV RNA >100,000 copies/mL.
copies/mL. At week 24, 90% of participants had HIV RNA <50 copies/mL; there were similar response rates in participants with baseline HIV RNA >100,000 copies/mL and ≤100,000 copies/mL (89% and 90%, respectively). Three participants experienced virologic failure, all of whom had suboptimal adherence; one participant developed an NRTI resistance mutation (M184V) and an INSTI resistance mutation (R263K).132

The Panel’s Recommendation:

- On the basis of these study results, the Panel recommends the use of DTG plus 3TC in ART-naive adults with baseline HIV RNA <500,000 copies/mL in instances where ABC, TAF, or TDF cannot be used or are not optimal (BI).

- Preliminary data from an observational study in Botswana suggest that there may be an increased risk of NTDs in infants born to those who were receiving DTG at the time of conception.6,7 Clinicians should refer to Table 6b prior to initiation of DTG in those who are pregnant or those who are of childbearing potential.

Darunavir/Ritonavir plus Lamivudine (DRV/r plus 3TC)

- In the ANDES trial, 145 participants were randomized 1:1 to receive open-label, once-daily dual therapy with DRV/r plus 3TC or triple therapy with DRV/r plus TDF/3TC. This study was conducted in Argentina, and the researchers used an FDC of DRV/r 800 mg/100 mg that is available in that country. The median baseline HIV RNA was 4.5 log10 copies, and 24% of participants had HIV RNA >100,000 copies/mL. At week 48, 93% of the participants in the dual-therapy group and 94% of the participants in the triple-therapy group achieved an HIV RNA <50 copies/mL; dual therapy was noninferior to triple therapy.25 The dual- and triple-therapy groups had similar rates of virologic suppression among study participants who had pre-therapy HIV RNA levels >100,000 copies/mL (91% and 92%, respectively).

The Panel’s Recommendation:

- On the basis of results from a small study with a relatively short follow-up period, DRV/r plus 3TC can be considered for use in people who cannot take ABC, TAF, or TDF (CI). Although the ANDES trial supports the use of DRV/r plus 3TC, it is smaller than other trials of NRTI-limiting regimens, and larger studies are warranted.

Darunavir/Ritonavir plus Raltegravir (DRV/r plus RAL)

- In the NEAT/ANRS 143 study, 805 treatment-naive participants were randomized to receive twice-daily RAL or once-daily TDF/FTC, each with DRV/r (800 mg/100 mg once daily). At week 96, DRV/r plus RAL was noninferior to DRV/r plus TDF/FTC based on the primary endpoint of proportion of patients with virologic or clinical failure. Among those with baseline CD4 cell counts <200 cells/mm3, however, there were more failures in the two-drug arm; a trend towards more failure was also observed for those with pretreatment HIV RNA ≥100,000 copies/mL.24 High rates of virologic failure in patients with HIV RNA >100,000 copies/mL were also seen in two smaller studies of DRV/r plus RAL.153,154

The Panel’s Recommendation:

- On the basis of these study results, the Panel recommends that DRV/r plus RAL be considered for use only in patients with HIV RNA <100,000 copies/mL and CD4 cell counts ≥200 cells/mm3, and only in those patients who cannot take ABC, TAF, or TDF (CI).

A Nucleoside-Limiting Regimen that is Efficacious but has Disadvantages

Lopinavir/Ritonavir plus Lamivudine (LPV/r plus 3TC)

- In the GARDEL study, 426 ART-naive patients were randomized to receive twice-daily LPV/r plus either

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

Downloaded from https://aidsinfo.nih.gov/guidelines on 1/11/2019
open-label 3TC (twice daily) or two NRTIs selected by the study investigators. At 48 weeks, a similar proportion of patients in each arm had HIV RNA <50 copies/mL (88.3% vs. 83.7%), meeting the study’s noninferiority criteria. The LPV/r plus 3TC regimen was better tolerated than the LPV/r plus two NRTI regimen.155

- This regimen is used infrequently due to the requirement of twice-daily dosing, the relatively high pill burden (a total of 5–6 tablets per day), and the adverse effect profile of LPV/r. In view of these substantial limitations, the Panel recommends that LPV/r plus 3TC be considered for use only in patients who cannot take ABC, TAF, or TDF and in whom the other alternatives listed above cannot be used (CI).

### Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy

**Note:** All drugs within an ARV class are listed in alphabetical order.

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantage(s)</th>
<th>Disadvantage(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual-NRTI</td>
<td>ABC/3TC</td>
<td>• Coformulated with DTG</td>
<td>• May cause life-threatening HSRs in patients who test positive for the HLA-B<em>5701 allele. As a result, HLA-B</em>5701 testing is required before use.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Generic formulations are available for ABC/3TC, ABC, and 3TC.</td>
<td>• In the ACTG 5202 study, patients with baseline HIV RNA ≥100,000 copies/mL showed inferior virologic responses when ABC/3TC was given with EFV or ATV/r as opposed to TDF/FTC. This difference was not seen when ABC/3TC was used in combination with DTG.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• ABC use has been associated with CV disease and cardiac events in some, but not all, observational studies.</td>
</tr>
<tr>
<td>TAF/FTC</td>
<td></td>
<td>• Coformulated with BIC, DRV/c, EVG/c, or RPV</td>
<td>• TDF is associated with lower lipid levels than TAF, perhaps because TDF results in higher plasma levels of tenofovir, which lowers lipids.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Active against HBV; a recommended dual-NRTI option for patients with HIV/HBV coinfection</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Smaller decline in renal function, less proteinuria, and smaller reductions in BMD than TDF/FTC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Approved for patients with eGFR ≥30 mL/min</td>
<td></td>
</tr>
<tr>
<td>TDF/3TC</td>
<td></td>
<td>• Coformulated with DOR and EFV</td>
<td>• Renal toxicity, including proximal tubulopathy and acute or chronic renal insufficiency, especially when combined with pharmacologic boosters.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Available as the following generic formulations:</td>
<td>• Osteomalacia has been reported as a consequence of proximal tubulopathy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• TDF</td>
<td>• Decreased BMD has been associated with use of TDF, especially when combined with pharmacologic boosters.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 3TC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• TDF/3TC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EFV/TDF/3TC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Long-term clinical experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Active against HBV</td>
<td></td>
</tr>
<tr>
<td>TDF/FTC</td>
<td></td>
<td>• Coformulated with EFV, EVG/c, and RPV as STRs</td>
<td>• Renal toxicity, including proximal tubulopathy and acute or chronic renal insufficiency, especially when combined with pharmacologic boosters.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Active against HBV; a recommended dual-NRTI option for patients with HIV/HBV coinfection</td>
<td>• Osteomalacia has been reported as a consequence of proximal tubulopathy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Better virologic responses than ABC/3TC in patients with baseline viral loads ≥100,000 copies/mL when combined with ATV/r or EFV</td>
<td>• Decreased BMD has been associated with use of TDF, especially when combined with pharmacologic boosters.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Associated with lower lipid levels than ABC or TAF</td>
<td></td>
</tr>
</tbody>
</table>
### Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (page 2 of 5)

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantage(s)</th>
<th>Disadvantage(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTI</td>
<td>BIC</td>
<td>• Coformulated with TAF/FTC</td>
<td>• Compared to other INSTIs, BIC has the shortest post-marketing experience.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• In trials in ART-naive participants, BIC resistance was not detected</td>
<td>• Oral absorption of BIC can be reduced by simultaneous administration with drugs or supplements containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 19d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No food requirement</td>
<td>• Inhibits tubular secretion of creatinine without affecting glomerular function.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Compared to other INSTIs, BIC has the shortest post-marketing experience.</td>
<td>• CYP3A4 and UGT1A1 substrate (but not a CYP3A4 inducer or inhibitor); potential for drug interactions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Oral absorption of BIC can be reduced by simultaneous administration with drugs or supplements containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 19d.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Inhibits tubular secretion of creatinine without affecting glomerular function.</td>
<td>• CYP3A4 and UGT1A1 substrate (but not a CYP3A4 inducer or inhibitor); potential for drug interactions.</td>
</tr>
<tr>
<td>DTG</td>
<td></td>
<td>• Higher barrier to resistance than EVG or RAL</td>
<td>• Preliminary data suggests that DTG use before pregnancy and through conception may be associated with an increased risk of NTDs in the infant. See text and Table 6b for recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Coformulated with ABC and 3TC</td>
<td>• Oral absorption of DTG can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 19d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No food requirement</td>
<td>• Inhibits renal tubular secretion of Cr and can increase serum Cr without affecting glomerular function.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No CYP3A4 interactions</td>
<td>• UGT1A1 substrate; potential for drug interactions (see Table 19d).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Favorable lipid profile</td>
<td>• Depression and suicidal ideation (rare; usually in patients with pre-existing psychiatric conditions).</td>
</tr>
<tr>
<td>EVG/c</td>
<td></td>
<td>• Coformulated with TDF/FTC or TAF/FTC</td>
<td>• EVG/c/TDF/FTC is only recommended for patients with baseline CrCl ≥70 mL/min; this regimen should be discontinued if CrCl decreases to &lt;50 mL/min.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Compared with ATV/r, causes smaller increases in total and LDL cholesterol</td>
<td>• COBI is a potent CYP3A4 inhibitor, which can result in significant interactions with CYP3A substrates.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EVG/c/TDF/FTC is only recommended for patients with baseline CrCl ≥70 mL/min; this regimen should be discontinued if CrCl decreases to &lt;50 mL/min.</td>
<td>• Oral absorption of EVG can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 19d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• COBI inhibits active tubular secretion of Cr and can increase serum Cr without affecting renal glomerular function.</td>
<td>• COBI inhibits active tubular secretion of Cr and can increase serum Cr without affecting renal glomerular function.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Has a lower barrier to resistance than boosted PI-, BIC-, or DTG-based regimens.</td>
<td>• Has a lower barrier to resistance than boosted PI-, BIC-, or DTG-based regimens.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Food requirement</td>
<td>• Food requirement.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Depression and suicidal ideation (rare; usually in patients with pre-existing psychiatric conditions).</td>
<td>• Depression and suicidal ideation (rare; usually in patients with pre-existing psychiatric conditions).</td>
</tr>
</tbody>
</table>
### Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (page 3 of 5)

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantage(s)</th>
<th>Disadvantage(s)</th>
</tr>
</thead>
</table>
| INSTI, continued | RAL | • Compared to other INSTIs, has longest post-marketing experience  
• No food requirement  
• No CYP3A4 interactions  
• Favorable lipid profile | • Has a lower barrier to resistance than boosted PI-, BIC-, or DTG-based regimens.  
• Increases in creatine kinase, myopathy, and rhabdomyolysis have been reported.  
• Rare cases of severe HSRs (including SJS and TEN) have been reported.  
• Higher pill burden than other INSTI-based regimens.  
• No STR formulation.  
• Oral absorption of RAL can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements, or multivitamin tablets with minerals). See dosing recommendations in Table 19d.  
• UGT1A1 substrate; potential for drug interactions (see Table 19d).  
• Depression and suicidal ideation (rare; usually in patients with pre-existing psychiatric conditions). |
| NNRTI | DOR | • Coformulated with TDF/3TC  
• Compared to EFV, CNS side effects are less frequent  
• No food requirement  
• Favorable lipid profile | • Shorter-term clinical experience than with EFV and RPV.  
• Potential for CYP450 drug interactions (see Tables 19b, 20a and 20b).  
• Treatment-emergent DOR resistance mutations may confer resistance to certain NNRTIs. |
| EFV | • EFV 600 mg is coformulated with TDF/FTC and TDF/3TC  
• EFV 400 mg is coformulated with TDF/3TC  
• EFV 600-mg dose has long-term clinical experience and EFV-based regimens (except for EFV plus ABC/3TC) have well-documented efficacy in patients with high HIV RNA | • Short-and long-term neuro-psychiatric (CNS) side effects, including depression and, in some studies, suicidality and catatonia. Screening for depression and suicidality is recommended in people with HIV who are taking a regimen that includes EFV.  
• Teratogenic in nonhuman primates, although no rate increase has been seen in humans.  
• Dyslipidemia  
• Rash  
• QTc interval prolongation; consider using an alternative to EFV in patients taking medications with known risk of causing Torsades de Pointes or in those at higher risk of Torsades de Pointes.  
• Transmitted resistance is more common than with PIs and INSTIs.  
• Greater risk of resistance at the time of treatment failure than with PIs.  
• Potential for CYP450 drug interactions (see Tables 19b and 20a).  
• Should be taken on an empty stomach (food increases drug absorption and CNS toxicities). |
Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (page 4 of 5)

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantage(s)</th>
<th>Disadvantage(s)</th>
</tr>
</thead>
</table>
| NNRTI, continued | RPV | • Coformulated with TDF/FTC and TAF/FTC  
• RPV/TDF/FTC and RPV/TAF/FTC have smaller pill sizes than other coformulated ARV drugs  
• Compared with EFV:  
  • Fewer CNS adverse effects  
  • Fewer lipid effects  
  • Fewer rashes  
• Not recommended in patients with pre-ART HIV RNA >100,000 copies/mL or CD4 cell counts <200 cells/mm³ because of higher rate of virologic failure in these patients.  
• Depression and suicidality  
• QTc interval prolongation; consider using an alternative to RPV in patients taking medications with known risk of causing Torsades de Pointes or in those at higher risk of Torsades de Pointes.  
• Rash  
• Transmitted resistance is more common than with PIs and INSTIs.  
• More NNRTI-, TDF-, and 3TC-associated mutations at virologic failure than with regimens that contain EFV and 2 NRTIs.  
• Potential for CYP450 drug interactions (see Tables 19b and 20a).  
• Meal requirement (>390 kcal)  
• Requires acid for adequate absorption.  
• Contraindicated with PPIs.  
• Use with H2 antagonists or antacids with caution (see Table 19a for detailed dosing information). |
| PIs | ATV/c or ATV/r | • Higher barrier to resistance than NNRTIs, EVG, and RAL  
• PI resistance at the time of treatment failure is uncommon with PK-enhanced PIs  
• ATV/c and ATV/r have similar virologic activity and toxicity profiles  
• Observational cohort studies have found an association between some PIs (DRV, LPV/r, FPV, IDV) and an increased risk of CV events; this risk has not been seen with ATV. Further study is needed. See text for discussion.  
• Individual ATV and RTV components available as generics  
• Commonly causes indirect hyperbilirubinemia, which may manifest as scleral icterus or jaundice.  
• Food requirement  
• Absorption depends on food and low gastric pH (see Table 19a for interactions with H2 antagonists, antacids, and PPIs).  
• Nephrolithiasis, cholelithiasis, nephrotoxicity  
• GI adverse effects  
• CYP3A4 inhibitors and substrates: potential for drug interactions (see Table 19a).  
• Food requirement  
• GI adverse effects  
• CYP3A4 inhibitors and substrates: potential for drug interactions (see Table 19a). |
| ATV/c (Specific considerations) | • Coformulated tablet  
• COBI inhibits active tubular secretion of Cr and can increase serum Cr without affecting renal glomerular function.  
• Coadministration with TDF is not recommended in patients with CrCl <70 mL/min.  
• COBI (like RTV) is a potent CYP3A4 inhibitor, which can result in significant interactions with CYP3A substrates. |
| DRV/c or DRV/r | • Higher barrier to resistance than NNRTIs, EVG, and RAL  
• PI resistance at the time of treatment failure is uncommon with PK-enhanced PIs  
• Skin rash  
• Food requirement  
• GI adverse effects  
• CYP3A4 inhibitors and substrates: potential for drug interactions (see Table 19a).  
• Increased CV risk reported in one observational cohort study. |
Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (page 5 of 5)

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantage(s)</th>
<th>Disadvantage(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI, continued</td>
<td>DRV/c (Specific considerations)</td>
<td>• Coformulated as DRV/c and DRV/c/TAF/FTC</td>
<td>• COBI inhibits active tubular secretion of Cr and can increase serum Cr without affecting renal glomerular function. • Coadministration with TDF is not recommended in patients with CrCl &lt;70 mL/min. • COBI (like RTV) is a potent CYP3A4 inhibitor, which can result in significant interactions with CYP3A substrates.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Only RTV-coformulated PI</td>
<td>• Requires RTV 200 mg per day. • Possible higher risk of MI associated with cumulative use of LPV/r. • PR and QT interval prolongation have been reported. Use with caution in patients at risk of cardiac conduction abnormalities or in patients receiving other drugs with similar effects. • Possible nephrotoxicity • CYP3A4 inhibitors and substrates: potential for drug interactions (see Table 19a).</td>
</tr>
</tbody>
</table>

Key to Acronyms: 3TC = lamivudine; ABC = abacavir; Al = aluminum; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; BMD = bone mineral density; Ca = calcium; CD4 = CD4 T lymphocyte; CNS = central nervous system; COBI = cobicistat; Cr = creatinine; CrCl = creatinine clearance; CV = cardiovascular; CYP = cytochrome P; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; eGFR = estimated glomerular filtration rate; EFV = efavirenz; EG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDC = fixed-dose combination; FPV = fosamprenavir; FTC = emtricitabine; GI = gastrointestinal; HBV = hepatitis B virus; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; IDV = indinavir; INSTI = integrase strand transfer inhibitor; LDL = low-density lipoprotein; LPV = lopinavir; LPV/r = lopinavir/ritonavir; Mg = magnesium; MI = myocardial infarction; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; PI = protease inhibitor; PK = pharmacokinetic; PPI = proton pump inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson syndrome; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrosis; UGT = uridine diphosphate glucuronosyltransferase

Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy (page 1 of 3)

<table>
<thead>
<tr>
<th>ARV Components or Regimens</th>
<th>Reasons for Not Recommending as Initial Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRTIs</td>
<td></td>
</tr>
<tr>
<td>ABC/3TC/ZDV (Coformulated)</td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td>As triple-NRTI combination regimen</td>
<td></td>
</tr>
<tr>
<td>ABC/3TC/ZDV plus TDF</td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td>As quadruple-NRTI combination regimen</td>
<td></td>
</tr>
<tr>
<td>d4T plus 3TC</td>
<td>• Significant toxicities (including lipoatrophy, peripheral neuropathy) and hyperlactatemia (including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis)</td>
</tr>
<tr>
<td>ddl plus 3TC (or FTC)</td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td>ddl plus TDF</td>
<td>• High rate of early virologic failure</td>
</tr>
<tr>
<td></td>
<td>• Rapid selection of resistance mutations</td>
</tr>
<tr>
<td></td>
<td>• Potential for immunologic nonresponse/CD4 cell decline</td>
</tr>
<tr>
<td></td>
<td>• Increased ddl drug exposure and toxicities</td>
</tr>
<tr>
<td>ARV Components or Regimens</td>
<td>Reasons for Not Recommending as Initial Therapy</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>NRTIs, continued</strong></td>
<td></td>
</tr>
<tr>
<td>ZDV/3TC</td>
<td>• Greater toxicities (including bone marrow suppression, GI toxicities, skeletal muscle myopathy, cardiomyopathy, and mitochondrial toxicities such as lipoatrophy, lactic acidosis, and hepatic steatosis) than recommended NRTIs</td>
</tr>
<tr>
<td><strong>NNRTIs</strong></td>
<td></td>
</tr>
<tr>
<td>DLV</td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td>ETR</td>
<td>• Insufficient data in ART-naive patients</td>
</tr>
<tr>
<td>NVP</td>
<td>• Associated with serious and potentially fatal toxicity (hepatic events and severe rash, including SJS and TEN)</td>
</tr>
<tr>
<td></td>
<td>• When compared to EFV, NVP did not meet noninferiority criteria</td>
</tr>
<tr>
<td><strong>PIs</strong></td>
<td></td>
</tr>
<tr>
<td>ATV (Unboosted)</td>
<td>• Less potent than boosted ATV</td>
</tr>
<tr>
<td>DRV (Unboosted)</td>
<td>• Use without RTV or COBI has not been studied</td>
</tr>
<tr>
<td>FPV (Unboosted) or FPV/r</td>
<td>• Virologic failure with unboosted FPV-based regimen may result in selection of mutations that confer resistance to FPV and DRV</td>
</tr>
<tr>
<td></td>
<td>• Less clinical trial data for FPV/r than for other RTV-boosted PIs</td>
</tr>
<tr>
<td>IDV (Unboosted)</td>
<td>• Inconvenient dosing (3 times daily with meal restrictions)</td>
</tr>
<tr>
<td></td>
<td>• Fluid requirement</td>
</tr>
<tr>
<td></td>
<td>• IDV toxicities, such as nephrolithiasis and crystalluria</td>
</tr>
<tr>
<td>IDV/r</td>
<td>• Fluid requirement</td>
</tr>
<tr>
<td></td>
<td>• IDV toxicities, such as nephrolithiasis and crystalluria</td>
</tr>
<tr>
<td>LPV/r</td>
<td>• Higher pill burden than other PI-based regimens</td>
</tr>
<tr>
<td></td>
<td>• Higher RTV dose than other PI-based regimens</td>
</tr>
<tr>
<td></td>
<td>• GI intolerance</td>
</tr>
<tr>
<td>NFV</td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td></td>
<td>• Diarrhea</td>
</tr>
<tr>
<td>RTV as sole PI</td>
<td>• High pill burden</td>
</tr>
<tr>
<td></td>
<td>• GI intolerance</td>
</tr>
<tr>
<td></td>
<td>• Metabolic toxicity</td>
</tr>
<tr>
<td>SQV (Unboosted)</td>
<td>• Inadequate bioavailability</td>
</tr>
<tr>
<td></td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td>SQV/r</td>
<td>• High pill burden</td>
</tr>
<tr>
<td></td>
<td>• Can cause QT and PR prolongation; requires pretreatment and follow-up ECG</td>
</tr>
<tr>
<td>TPV/r</td>
<td>• Inferior virologic efficacy</td>
</tr>
<tr>
<td></td>
<td>• Higher rate of adverse events than other RTV-boosted PIs</td>
</tr>
<tr>
<td></td>
<td>• Higher dose of RTV required for boosting than other RTV-boosted PIs</td>
</tr>
<tr>
<td><strong>Entry Inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>T-20</td>
<td>• Only studied in patients with virologic failure</td>
</tr>
<tr>
<td></td>
<td>• Twice-daily subcutaneous injections</td>
</tr>
<tr>
<td></td>
<td>• High rate of injection site reactions</td>
</tr>
<tr>
<td>IBA (CD4 Post-Attachment Inhibitor)</td>
<td>• Only studied in a very small number of patients with virologic failure</td>
</tr>
<tr>
<td></td>
<td>• Requires IV therapy</td>
</tr>
<tr>
<td></td>
<td>• High cost</td>
</tr>
</tbody>
</table>
Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy (page 3 of 3)

<table>
<thead>
<tr>
<th>ARV Components or Regimens</th>
<th>Reasons for Not Recommending as Initial Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Entry Inhibitors</strong></td>
<td></td>
</tr>
</tbody>
</table>
| MVC                        | • Requires testing for CCR5 tropism before initiation of therapy  
                            | • No virologic benefit when compared with other recommended regimens  
                            | • Requires twice-daily dosing |

Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; CD4 = CD4 T lymphocyte; COBI = cobicistat; d4T = stavudine; ddl = didanosine; DLV = delavirdine; DRV = darunavir; ECG = electrocardiogram; EFV = efavirenz; ETR = etravirine; FPV = fosamprenavir; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; GI = gastrointestinal; IBA =ibalizumab; IDV = indinavir; IDV/r = indinavir/ritonavir; IV = intravenous; LPV = lopinavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RTV = ritonavir; SJS = Stevens Johnson Syndrome; SQV = saquinavir; SQV/r = saquinavir/ritonavir; T-20 = enfuvirtide; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrolysis; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine

References


null


48. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health


65. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus *Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV* F-47


Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

Downloaded from https://aidsinfo.nih.gov/guidelines on 1/11/2019


129. Efavirenz (400)/lamivudine/tenofovir disoproxil fumarate (Symfi Lo) [package insert]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208255s000lbl.pdf.


Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV